



Cite this: *Nanoscale*, 2021, **13**, 16405

Manganese-based advanced nanoparticles for biomedical applications: future opportunity and challenges

Shagufta Haque, ^{a,b} Sanchita Tripathy ^{a,b} and Chitta Ranjan Patra ^{*a,b}

Nanotechnology is the most promising technology to evolve in the last decade. Recent research has shown that transition metal nanoparticles especially manganese (Mn)-based nanoparticles have great potential for various biomedical applications due to their unique fundamental properties. Therefore, globally, scientists are concentrating on the development of various new manganese-based nanoparticles (size and shape dependent) due to their indispensable utilities. Although numerous reports are available regarding the use of manganese nanoparticles, there is no comprehensive review highlighting the recent development of manganese-based nanomaterials and their potential applications in the area of biomedical sciences. The present review article provides an overall survey on the recent advancement of manganese nanomaterials in biomedical nanotechnology and other fields. Further, the future perspectives and challenges are also discussed to explore the wider application of manganese nanoparticles in the near future. Overall, this review presents a fundamental understanding and the role of manganese in various fields, which will attract a wider spectrum of the scientific community.

Received 30th July 2021,
Accepted 6th September 2021

DOI: 10.1039/d1nr04964j

rsc.li/nanoscale

^aDepartment of Applied Biology, CSIR-Indian Institute of Chemical Technology, Uppal Road, Tarnaka, Hyderabad - 500007, Telangana State, India.
E-mail: crpatra@iict.res.in, patra.chitta@gmail.com; <https://www.iictindia.org/People/view?id=92>, <https://scholar.google.co.in/citations?user=uyaWkGQAAAAJ&hl=en>; Tel: +91-40-27191855

^bAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, U.P., India

1. Background of manganese

Currently, the exploration of transition metal nanoparticles has attracted increasing attention because of their revolutionary and promising properties in certain areas such as drug delivery, anticancer therapeutics, antimicrobial activities, and bioimaging.^{1–5} Among the transition metal nanoparticles,



Shagufta Haque

Shagufta Haque received her B.Sc. (2015) and M.Sc. (2017) in Zoology from Lady Brabourne College and University of Calcutta, Ballygunge Campus. She secured 59th rank in Ph.D. entrance exam (CSIR-UGC-NET) held at the national level in December 2017 and joined Dr Patra's group at the CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad as a CSIR-JRF in 2018. Currently, she

works at the Department of Applied Biology and her Ph.D. research involves the design and development of advanced novel nanomaterials for drug delivery in angiogenesis, wound healing and ischemic diseases.



Sanchita Tripathy

Sanchita Tripathy received her B.Sc. (2016) and M.Sc. (2018) in Zoology from Utkal University. She received her MPhil (2020) in Life Sciences from Sambalpur University. She secured 80th rank in CSIR UGC JRF (NET) exam organized by Council of Scientific and Industrial Research, New Delhi, Govt. of India, held in December 2019. She joined Dr Patra's group at the CSIR-Indian Institute of Chemical Technology

(CSIR-IICT), Hyderabad as a UGC-JRF in 2021. Currently, she works at the Department of Applied Biology and her Ph.D. research involves the design and development of advanced nanomedicines for cancer therapeutics.

manganese (Mn) nanoparticles have attracted the most attention for applications such as solar cells, magnetic storage devices, biological applications such as molecular sieves and bioimaging due to their chemical as well as physical features.^{6–9} Manganese is the third most abundant transition element after iron and titanium, and the twelfth most common element on Earth.^{10,11} Manganese (Mn) with different oxidation states is present in the Earth's crust and the particulate matter in the atmosphere and water. Manganese is present as different 3d transition metal oxides such as MnO, MnO₂, Mn₂O₃, Mn₃O₄ and Mn₅O₈.¹² In living systems, manganese is considered a necessary micro-nutrient for growth, metabolism, reproduction, *etc.*, which is acquired through food and water.^{13–15} Inside the human body, Mn is absorbed mainly through the gastrointestinal tract together with lungs. Mn is utilized in cellular energy regulation, blood clotting, connective tissue and bone growth, brain development, *etc.*^{16–22}

The reference daily intake (RDI) of Mn suggested by the U. S. Food and Drug Administration (U.S. FDA) is 2–5 mg day⁻¹ for adults. This dosage has been suggested to be safe by the U. S. National Research Council (NRC).²³ The requirement for Mn varies depending on gender and life stage. The difference in Mn requirements is attributed to the fact that women have lower concentrations of serum ferritin than men. Furthermore, lactating women require more Mn.²⁴ However, manganese in the form of composites has certain disadvantages such as short blood circulation time and accumulation in the brain, resulting in changes in the central nervous system followed by cognitive and movement abnormalities. Therefore, the necessity of Mn and the limitations of its complexes have encouraged scientists to explore Mn in the form of nanoparticles.^{25–27}

Manganese-based nanomaterials are ecofriendly, economical, biocompatible, and possess strong adsorption property,

and thus are suitable for different biological applications such as drug delivery, anticancer, antimicrobial, antioxidants, nanozymes, photothermal therapy, and biosensing.^{27–39} Although several articles have been reported regarding the utilization of manganese nanoparticles, there is no comprehensive review article on the most recent development of manganese-based nanoparticles for biomedical applications together with their challenges and future perspective. Considering their implications in healthcare and other issues, the present review article focuses on the background and different aspects of manganese and its nanoforms for various biological applications. Finally, considering their commercial opportunity in the near future, the mechanism of the actions and toxicological update of manganese nanoparticles are also discussed.

2. Historical and industrial development

Manganese has been used for decades in industrial and biological development. The use of manganese can be traced back to the Stone Age, where it was used as a pigment for cave paintings.^{40–42} The use of manganese as the black ore pyrolusite (manganese dioxide) in cave paintings has been well documented in the Upper Paleolithic period (17 000 years ago) or Stone Age. Manganese (found in iron ore) was utilized by Spartans in ancient Greece to develop steel weapons. Up to the 14th century, Mn was used by Roman and Egyptian glass makers to either remove or add color to glass.⁴⁰ In 1774, Johan Gottlieb Gahn, a Swedish mineralogist, isolated manganese as a metal component from pyrolusite.⁴¹ The word manganese originated either from the Latin word 'magnes' for magnet or 'magnesia nigra', meaning black magnesium oxide.⁴³ The Greek word for manganese is 'magic'.⁴⁴ In 17th century, Glauber, a German chemist, developed permanganate, the first functional manganese salt. Subsequently, Carl Wilhelm, a Swedish chemist, produced chlorine using MnO₂.⁴¹

At the commencement of the 19th century, manganese was used in steel making.⁴⁵ In 1816, a German scientist discovered the properties of manganese in steel making, where it increases the hardness of iron without affecting its toughness and malleability. Ferromanganese was produced with a high content of manganese first by Prieger (1826), and later by Pourcel (1875). The major breakthrough occurred in 1860 when Sir Henry Bessemer used spiegeleisen to remove sulphur and excess oxygen from steel, paving the way towards modern industrialization. The discovery of the Leclanche cell, which contains MnO₂, increased the demand for manganese on a large scale.⁴⁶ Large-scale commercial production utilizing Mn started in the 20th century for chemical and metallurgical applications. Since then, the demand for manganese production has increased daily. Accordingly, to fulfill the rising demand for manganese in the 21st century, deep sea mining has been used for the extraction of manganese nodules.⁴⁷



Chitta Ranjan Patra

Dr Chitta Ranjan Patra received his Ph.D. in Chemistry from the CSIR-National Chemical Laboratory (NCL), Pune. Dr Patra is currently the Principal Scientist at the Department of Applied Biology, CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad. He is also an Associate Professor of Biological Sciences in the Academy of Scientific & Innovative Research (AcSIR), Ghaziabad. Dr Patra's

research group is pursuing various nanomedicine research projects aimed at developing advanced biomaterial- and nanoparticle-based drug delivery systems (DDS) for the treatment of cancer, cardiovascular and ischemic disease, wounds and bacterial infection.

3. Presence of manganese in living systems

Manganese is a crucial nutrient essential for different metabolic functions required for normal human development.^{15,16,48} Mn has also been reported to be involved in the synthesis and activation of enzymes, metabolism of lipids and glucose, protein synthesis, hematopoiesis, endocrine regulation and immunological functions.^{15,16,49–52} The metalloenzymes of Mn such as phosphoenolpyruvate decarboxylase, Mn superoxide dismutase (MnSOD), glutamine synthetase and arginase help in the metabolic processes together with scavenging free radicals, leading to a reduction in oxidative stress.^{13,15,18,53–55} The absorbed Mn becomes further available to other mitochondrial-rich organs especially the pituitary, liver and pancreas.⁵⁶ The following sections discuss the role of Mn at different cellular and subcellular levels.

3.1. Enzymes

Enzymes are defined as biological catalysts, which at a certain range of optimum environmental conditions of pH, temperature and pressure within cells, carry out biochemical reactions with increased specificity and efficiency.⁵⁴ For the proper functioning of enzymes, metal ions are required for the catalytic process, to maintain their structure, *etc.* Some enzymes have manganese-based catalytic activity.^{13,54,55} There are two categories of Mn-related enzymes, where one is Mn-activated/inactivated enzymes and the other Mn-containing enzymes.^{13,55,57} Mn-activated enzymes are rapidly reversible, tight, and have specific sites that form complexes with manganese for either regulatory or catalytic function.^{13,58} Conversely, Mn-containing enzymes include manganese superoxide dismutase and arginase. Moreover, Mn has a specific role in the different enzyme classes such as oxidoreductases, transferases, hydroxylases, lyases and ligases.⁴⁹

Oxidoreductases are a class of enzymes responsible for redox reactions. The oxidoreductases that contain Mn include peroxidase, catalase, hydroxylase, and manganese superoxide dismutase (MnSOD).⁵⁹ MnSOD, catalase and peroxidase protect cells from potentially damaging radical species.^{18,53,60,61} Transferases are a group of enzymes responsible for the transfer of functional groups between two molecules. The enzymes that require Mn for their proper functioning are glycosyl-transferases, protein kinases, DNA and RNA polymerases and a few sulpho-transferases.^{17,18} Among the hydroxylases, the enzymes that carry out specific functions such as growth, metabolic and cellular functions are reportedly Mn dependent such as are peptidases, amidases, proteinases, hydrolases of ATP and organo-phosphates. The other Mn-specific hydroxylases include cyclic nucleotide phosphodiesterase, phosphoinositol phosphatases, phospholipase C and several *exo*- and *endo*-nucleases.^{17,62} Some enzymes of the lyase group are activated by Mn, for example, phosphoenolpyruvate carboxykinase, guanylate and adenylate cyclases,

which are required in cell regulation and metabolism.⁶³ The ligases help to catalyze biosynthesis reactions *via* the lysis of ATP. The enzymes in the class ligase that contain Mn are alanyl-tRNA synthetase, glutamine synthetase and pyruvate carboxylase.⁶⁴ Therefore, all these enzymes need Mn for their proper functioning and regulation of cellular function.

3.2. Neurotransmitters

Neurotransmitters are chemicals present endogenously for signal transmission from one neuron to another neuron, gland or muscle.⁶⁵ Metal ions have various roles in the proper working of neurotransmitters such as zinc and manganese.^{48,65,66} Mn is required at micromolar concentrations for normal and proper functioning of the nervous system.^{48,66} Mn is needed during the uptake and release of neurotransmitters. Mn is also responsible for altered ATPase activity for the uptake of noradrenaline and dopamine in rat synaptosomes and in striatal tissue.⁶⁷ Manganese also changes the Ca(II) uptake and catecholamine secretion in cultured adrenal medulla cells. The ionic channels acting in response to the excitatory amino acids located in the hippocampal neurons are also Mn specific.²¹ Guanylate cyclase, one of the enzymes released by gonadotropin-releasing hormone, requires Mn for its activation.⁶⁸ There is a clear link between neurotransmitter regulation of neuronal adenylate cyclase and calmodulin activation by Mn.¹⁹ Mn affects the neurotransmitter receptors by changing the receptor binding site specificity and interaction with guanylate, adenylate cyclases, phosphatases and protein kinases for the regulation of intracellular enzymes or receptor together with stabilization of the interactions between the receptor subunits.^{18,20,63}

3.3. DNA–RNA interactions

The nucleic acids, DNA and RNA, are comprised of nucleoside building blocks attached through phosphodiester linkages. However, the nucleic acids require metal ions for the hydrolytic cleavage of the phosphodiester bonds and other biological activities.^{48,69,70} Manganese has been reported to interact with DNA and RNA. The relation between DNA and Mn was studied with the help of different biophysical techniques for the detection of ligand groups and conformational changes.⁷¹ The Mn has the ability to catalyze pre-biotic DNA production without the presence of any enzymes. As mentioned earlier, Mn plays a role in DNA and RNA polymerases.^{17,18} During the replication process, Mn takes part in mutagenesis through its interaction with DNA and DNA polymerase I.⁷² Mn even has effects on translational repressor together with double-stranded RNA-activated inhibitor.⁷³

3.4. Metabolism

Manganese plays a major role in the metabolic processes of the body together with the metabolism of prominent biomolecules.^{15,48,56} Mn helps in the metabolism of carbohydrates.¹⁵ PEP carboxykinase and pyruvate carboxylase are Mn specific, which are required for carbohydrate homeostasis, and thus excess or a deficiency in Mn affects the carbohydrate

equilibrium.^{15,74,75} Mn has been reported to have an insulin-mimicking effect.⁷⁶ Regarding lipid metabolism, there is a strong correlation between Mn and cholestasis given that Mn excretion takes place through the manganese–bilirubin complex.^{77,78} There are reports of altered high-density lipoprotein (HDL) compositions due to Mn deficiency.⁷⁹ The synthesis of phosphatidyl–inositol in different tissues is Mn dependent. Certain reports in the literature highlight the relationship between lipid peroxidation and developmental problems associated with Mn deficiency.^{15,48} The other effects of Mn include inhibition of deoxyribose degradation by manganese–superoxide dismutase. Mn is actively involved in the metabolism of drugs in the brain.^{48,70} Therefore, all these cases clearly indicate the indispensable role of Mn in metabolism in the human body.

3.5. Cellular effects

Mn is present in the cellular components of blood and in plasma. The transport, efflux and distribution of Mn through the plasma membrane of hepatocytes occur *via* facilitated diffusion.^{56,80} There are numerous tight binding sites for Mn in the cytoplasm of cells following its active transport into the mitochondria. The Mn distribution in the cell is 40% in the cytoplasm and 60% in mitochondria. The Mn distribution in mammalian cerebral cells is similar to that in hepatocytes, but its concentration is greater in mitochondria.⁸¹ As discussed in the previous section, Mn prevents cell damage due to the generation of free radicals.^{18,53,60,82} After crossing the blood brain barrier, Mn binds to transferrin and maintains iron homeostasis.⁸³ Consequently, Mn deficiency leads to convulsions and epilepsy.⁸⁴

In the case of hormones, Mn directly regulates glucagon, insulin, and carbohydrate metabolism by influencing their biosynthesis and release.⁸⁵ It has been reported that Mn injections are beneficial for glucagon release, which increases the blood glucose concentration.⁷⁴ Besides, Mn is also involved in the regulation of prostacyclin production in aortic endothelial cells, prostaglandin synthesis in hepatocytes, discharge of nor-adrenaline from the pulmonary artery, *etc.* Mn influences oxytocin analogues on the receptors present on mammary gland and myometrial membranes. With reference to the interaction of Mn with other elements, Mn manipulates calcium uptake in the sarcoplasmic reticulum. Mn also affects copper and zinc uptake.⁴⁹ In the case of heavy metal toxicity, Mn helps to increase tolerance towards cadmium hepatotoxicity and lethality.⁸⁶

3.6. Role of manganese for blood sugar regulation and diabetes

Manganese, as an essential trace element, is involved in maintaining normal immune responses, cellular energy, blood sugar regulation, protection against oxidative stress, *etc.*⁸⁷ Lower levels of Mn in the blood increases the risk of diabetes.^{87,88} In the case of diabetes, due to the high glucose level, various pathogenic pathways are initiated such as ROS. Further, the increased ROS affect the islet beta cells of the pan-

creas, leading to insulin resistance, diabetes and obesity. A relationship exists between the pancreas and Mn for maintaining the blood glucose level. Mn may accelerate insulin release from the pancreas to the bloodstream or glucagon inhibition, thereby increasing the cellular glucose uptake.⁸⁸ An Mn deficiency leads to lower insulin secretion from the pancreas, followed by its increased degradation.⁸⁹ Also, lower levels of Mn affect transport, glucose tolerance and enhance the risk of metabolic syndrome in adipose cells.^{15,90,91} Accordingly, Baly *et al.* demonstrated that Mn-deficient Sprague-Dawley rats showed a decrease in distal insulin receptors, leading to a decrease in glucose transport.⁹¹ This also affected the insulin-dependent glucose oxidation to CO₂ and lowered the conversion of triglycerides.⁹¹ The Mn porphyrin catalytic antioxidant (MnP) upregulates glucose oxidation, followed by reduced fatty acid oxidation. Further, Mn supplementation decreases the risk of endothelial problems in diabetes.⁹² Therefore, Mn-related carbohydrate metabolism is due to the role of Mn in insulin release and gluconeogenesis.¹⁵

Table 1 describes the role of manganese in living systems.^{17,18,21,53,63,64,67,73,74,76,77,83,86}

4. Synthetic approaches for manganese nanoparticles

Manganese as a metal has been found to have different applications inside the human body, and hence scientists worldwide are focusing on methods for its feasible synthesis.^{93–97} The synthetic procedures, precursors and reaction conditions lead to the formation of manganese nanoparticles of different shapes and sizes.^{98,99} The following section highlights the different synthetic approaches for the preparation of Mn nanoparticles, which are briefly described below:

- Chemical synthesis^{93,100,101}
- Physical synthesis^{102–106}
- Biological synthesis.^{95–97,107,108}

Table 1 Role of manganese in living systems

| Mn | Role of Mn | Function | Ref. |
|---|--------------------------------|---|------|
| Mn ^{II} / Mn ^{III} | Enzymatic | Anti-oxidant, metabolism, and cellular regulation | 18 |
| MnSOD | Antioxidant | Anti-oxidative/nitrosative stress | 53 |
| Mn ²⁺ | DNA replication | Mutagenesis | 17 |
| Mn ²⁺ | Enzymatic | Adenylate cyclase activity | 63 |
| Mn ²⁺ | Enzymatic | Stimulate ligase reaction | 64 |
| Mn | Neurotransmitter | Neurotransmitter synthesis and metabolism | 21 |
| Mn | Brain development | Changes in norepinephrine | 67 |
| Mn ²⁺ | Cellular translation | RNA-activated inhibitor | 73 |
| Mn | Lipid metabolism | Cholestasis | 77 |
| Mn | Carbohydrate | Insulin mimetic | 76 |
| Mn | Iron homeostasis | Binds to transferrin | 83 |
| Mn | Glucagon release | Blood glucose concentration | 74 |
| Mn | Heavy metal toxicity (cadmium) | Cadmium hepatotoxicity | 86 |

4.1. Chemical synthesis

The chemical methods used for the synthesis of Mn nanoparticles involve oxidation-reduction, hydrothermal methods and microemulsion techniques. The advantages underlying for chemical synthesis include less time consumption, greater yield and reduced expenditure of energy. There are several reports in the literature on chemically synthesized Mn-based nanoparticles. The chemical acts as a reducing agent and capping agent for the formation of nanoparticles.¹⁰⁰ Several chemicals are utilized for the synthesis of manganese nanoparticles such as polyvinylpyrrolidone (PVP), aqueous ammonia solution of KMnO_4 , and methyl acetate.^{93,100,101}

4.2. Physical synthesis

The physical methods involve the formation of Mn nanoparticles without the use of any chemical or biological precursors. There are different types of physical methods for the synthesis of nanoparticles, namely, evaporation–condensation, arc discharge, laser ablation, and thermal decomposition.^{102–106}

4.3. Biosynthesis

Recently, the green chemistry approach has been extensively used for the synthesis of various metal nanoparticles due to its features such as ecofriendly nature and easy synthesis. This approach overcomes the limitations of the use of harmful chemicals and excessive energy, which are generally used in industries.^{109–111} Similarly, manganese nanoparticles are synthesized using biological agents such as plants and microorganisms including bacteria and fungi.^{95–97,107,108} In this case, flower-shaped MnO_2 nanoparticles doped with silver were synthesized by Jana *et al.* via wet chemical procedures at low temperature.¹¹²

Manganese-based nanomaterials can be characterized using several analytical tools including XRD, FTIR, DLS, XPS, SEM, TEM, and HRTEM.^{93,96,100,101} Readers who want to know more about the synthesis of manganese-based nanoparticles can refer to the literature.^{93,95,96,100–107}

5. Physical and chemical properties of manganese

Manganese is the third most abundant transition element after iron and titanium, and is the twelfth most common element on Earth.^{10,11} Manganese (Mn), which is non-toxic and economic with different oxidation states, is present in the Earth's crust and particulate matter in the atmosphere and water.^{12,113} Mn exhibits efficient redox properties because its varying oxidation states, ranging from -3 to $+7$, and capacity to form compounds with a coordination number up to 7.5. This results in the use of high oxidation-state manganese species as strong oxidizing agents.¹¹³ Also, Mn in the form of oxides has several unique properties including redox property, surface nano-architectures and crystal structures.¹¹⁴ Manganese is effective in improving the catalytic activity in

several oxidation reactions.¹¹⁵ The other determining factors for catalytic activity are the size and morphology of manganese oxide catalysts in a structure-dependent sensitive reaction.¹¹⁶ Manganese has the ability to transform itself for a variety of redox functions.⁴⁴ There are several enzymes that require Mn for their proper functioning, as discussed in the previous sections. Mn catalases provide a platform for bioinorganic chemistry to mimic biological reactions.¹¹⁷ Mn-based catalysts act as substitutes for noble metals and oxides in a wide range of reactions.¹¹⁴

Because of the catalytic properties of manganese oxide, its nanoforms exhibit oxidase-like features, and hence are referred to as nanozymes.¹¹⁸ These features of manganese together with its multi oxidation states help it to act like an antioxidant and scavenge ROS.¹¹⁹ The activity of manganese nanozymes is dependent on their size, morphology, surface area and redox functions, which mimic the activity of redox enzymes such as superoxide dismutase, catalase and glutathione peroxidase. The role of manganese nanoparticles as nanozymes for biomedical applications is discussed in the sections below.^{34,118,120,121}

Manganese nanoparticles are being explored for drug delivery applications due to their large surface to volume ratio, increasing their sensitivity towards the tumor microenvironment.²⁷ Moreover, manganese nanoparticles act dually as on-demand and controlled systems for drug delivery applications. The tumor microenvironment is highly acidic and contains an increased concentration of glutathione (GSH). Hence, manganese nanoparticle-based drug delivery uses the concept of pH and GSH response for the release of drugs in a controlled manner.¹²² Manganese dioxide was recently studied for drug delivery applications and as a scaffold for stem cell transplantation and differentiation due to its biodegradable and non-toxic nature.¹²³ Several reports investigated the drug delivery applications of Mn nanoparticles, which are discussed in the subsequent sections.^{124–126}

6. Different biomedical applications

Manganese-based nanoparticles have been reported to be used for various biomedical applications such as photothermal therapy, fluorescence quenchers, biosensors, antimicrobial, and anti-angiogenic, all of which are discussed in the following subsections.^{27–35}

6.1. Drug delivery

Conventional therapies include chemotherapy, radiation and surgery. However, the most conveniently used chemotherapy has several disadvantages such as low bioavailability, low diffusion and retention capability, nonspecific targeting, multi-drug resistance, low therapeutic indices, and high dose accompanied with side effects.^{124–126} Accordingly, nanotechnology can play a significant role. Therefore, to reduce the adverse effects and increase the therapeutic efficacy of different drugs, scientists are focused on the design and devel-

opment of various inorganic nanomaterials (gold, silver, platinum, *etc.*) for efficient drug delivery or targeted drug delivery using suitable targeting agents.^{127–130} Recently, manganese-based nanoparticles have been extensively used for theranostics applications to overcome the above-mentioned difficulties. They have been found to be efficient systems for drug delivery due to their unique physico-chemical properties such as high surface to volume ratio in comparison to their bulk forms.^{27,122,131,132} This also increases their sensitivity towards the tumor microenvironment. Another exclusive point of using manganese nanoparticles for drug delivery is that they can be used both as on-demand and controlled systems. It is known that the tumor microenvironment is highly acidic and has a high concentration of glutathione (GSH). Hence, manganese nanoparticle drug delivery systems can be developed using the concept of pH and GSH response. Accordingly, Zhao *et al.* developed a silica-coated core of Fe₃O₄@SiO₂ linked with NaYF₄:Yb,Er shell (MSU)-modified MnO₂ nanosheets on the surface of nanoparticles for the loading and release of drugs.¹²² Fig. 1 shows an overall schematic representation for the stepwise development of the MSU/MnO₂-CR drug delivery system and its biological application. MSU was synthesized for fluorescence imaging and magnetic targeting, where the MnO₂ nanosheets act as quenchers for the system and a drug carrier. A multifunctional nanocomposite was further developed by loading Congo Red drug for delivery. The nanoformulation was used to check the level of intracellular GSH concentration. GSH reduced MnO₂ to Mn²⁺, thus leading to the release of the drug followed by turning on of its upconversion luminescence.¹²² Manganese nanoforms have been explored in the area of gene silencing treatment. For example, Fan *et al.* designed DNzyme-MnO₂ nanosheets for gene slicing treat-

ment.¹³¹ Chlorin e6-labelled DNzymes (Ce6) were adsorbed on the MnO₂ nanosheets to prevent their enzymatic digestion by endogenous nuclease. The nanosystem even inhibited Ce6 for ¹O₂ generation in the circulatory system. In the presence of GSH, the reduction of MnO₂ to Mn²⁺ released Ce6, which generated ¹O₂ for efficient photodynamic therapy. Mn²⁺ was also beneficial for GSH-modulated MRI of tumor cells. The modified nanosystem helped in bimodal cancer treatment.¹³¹

MnO₂ has a hollow space, which led scientists to explore its use for drug delivery due to its internal space, enhanced surface area, excellent permeability and low density. Exploring these characteristics, Xu *et al.* designed mesoporous manganese dioxide (mMnO₂) grown over silica-coated mesoporous upconversion nanoparticles (UCNPs@mSiO₂), which was further loaded with chlorin e6 and showed biodegradability in the tumor microenvironment.¹³² The loading of doxorubicin modified with polyethylene glycol in the mesoporous nanosystem was high due to its increased surface area. Inside the tumor microenvironment, GSH degraded mMnO₂ to Mn²⁺, releasing the doxorubicin. Also, the UCNPs were coupled with Mn²⁺, which resulted in enhanced trimodal imaging. Further, the nanosystem helped to alleviate tumor hypoxia *via* the reduction of glutathione and decomposition of endogenous H₂O₂, resulting in effective chemo-photodynamic treatment.¹³² Similarly, Ren *et al.* developed manganese/cobalt oxide nanoparticles with doxorubicin encapsulated in their hollow cavity, which were released in the environment of GSH and exhibited efficient anticancer activity both *in vitro* and *in vivo*.¹³³ Fig. 2(a and b) show the *in vivo* MRI and tumor treatment by the nanoparticles, where Fig. 2a shows the T₁-weighted and Fig. 2b the T₂-weighted MR images at different time points. Fig. 2c exhibits the tumor volume curve, which illustrates that the tumor treated with the manganese/cobalt oxide nanoparticles with doxorubicin showed the maximum inhibition. The body weight curves shown in Fig. 2d show the minimal weight loss in the nanoparticle drug-loaded group, indicating the lowest toxicity of the drug carriers. The longest survivability was observed in the manganese/cobalt oxide nanoparticles with doxorubicin-treated mice (Fig. 2e). Fig. 2f shows the histopathological analysis of the nanoparticle-treated tumor-bearing mice. Furthermore, the histopathological stain sections of the tumor also showed no difference between the nanoparticle-treated group and the other groups, exhibiting the safety of the manganese-based nanoparticles.¹³³ Recently, Wang and colleagues prepared superparamagnetic manganese ferrite nanoparticles (MnFe₂O₄) using a sonochemical method.¹³⁴ The NPs showed good hydrophilicity, low *in vitro* cytotoxicity and high drug loading capacity. Doxorubicin hydrochloride was loaded on the surface of the MnFe₂O₄ nanoparticles in a pH-dependent manner in the tumor microenvironment.¹³⁴ In another work, Zhang *et al.* designed hybrid nanomaterials (Au/MnO₂) *via* the combination of gold nanorods and mesoporous manganese dioxide, resulting in a multi-responsive (GSH, pH and NIR responsive) nanoplatform for drug delivery.¹³⁵ These conjugates showed a high doxorubicin drug loading capacity (through hydrogen bonding,




Fig. 1 Schematic illustration of the synthetic procedure for the preparation of the MSU/MnO₂-CR drug delivery system. Reprinted with permission from ref. 122 Zhao *et al.*, *Dalton Trans.*, 2014, 43, 451–457. Copyright©2014, The Royal Society of Chemistry.




Fig. 2 *In vivo* MRI and treatment of tumors by Dox-loaded MCO-70–Dox NPs. *In vivo* tumor (a) T_1 -weighted and (b) T_2 -weighted MR imaging before injection (0 h) and at different times (2 h, 15 h, and 24 h) after the injection of MCO-70–Dox NPs. (c) Tumor growth curves, (d) body weight curves, and (e) survival rate from the different treatment groups, which are PBS, MCO-70–Dox, Dox, and MCO, respectively. (f) Histological analyses of main organs from U87MG tumor-bearing nude mouse with intravenous injection of PBS and MCO–Dox NPs. Reprinted with permission from ref. 133 Ren *et al.*, *Nanoscale*, 2019, **11**, 23021–23026. Copyright©2019, The Royal Society of Chemistry.

electrostatic interaction and physical adsorption). The acidic environment and high GSH concentration of tumor cells were suitable for MnO_2 -based drug release. Fig. 3 exhibits an overall schematic representation of the preparation of the nanoparticles and their mechanism of drug release. The nano-




Fig. 3 Scheme of the preparation of Au/ MnO_2 nanoparticles and drug release of Au/ MnO_2 nanoparticles. Reprinted with permission from ref. 135 Zhang *et al.*, *Eng. Chem. Res.*, 2019, **58**, 2991–2999. Copyright©2019, the American Chemical Society.

particles displayed efficient responses towards GSH, pH and NIR.¹³⁵

6.2. Anti-angiogenesis for cancer

The process of angiogenesis is defined as the formation of new blood vessels from pre-existing ones.^{136,137} Although angiogenesis is required for several signaling pathways that are indispensable for proper functioning of living organisms, excessive angiogenesis is the root of many deadly diseases including cancer.¹³⁸ Tumor angiogenesis is regarded as one of the key processes occurring during the development of cancer.¹³⁹ Many chemotherapeutic agents target the inhibition of tumor angiogenesis to curb cancer. However, certain disadvantages regarding the specificity of commercial treatments have led to the use of nanoparticles. Manganese nanoparticles have been reported to exhibit anti-angiogenesis activity through the depletion of blood vessels in a chorioallantoic (CAM) membrane assay.¹⁴⁰ In another work, Chang *et al.* delivered MnO_2 nanoparticles in the hepatocellular carcinoma (HCC) tumor microenvironment to suppress and destroy the hypoxia-driven tumor.¹⁴¹ The synthesized nanoMnSor effectively delivered oxygen-producing MnO_2 and sorafenib (anti-angiogenic drug) in the HCC tumor microenvironment. The hypoxic condition was alleviated by MnO_2 by converting H_2O_2 into oxygen. *In vivo* treatment using these nanoparticles in a mouse orthotopic tumor model showed that sorafenib induced the suppression of primary tumor growth and decreased tumor vascularization and metastasis, helping the overall survival. NanoMnSor reprogrammed the hypoxic tumor microenvironment by reducing infiltration of tumor-associated macrophages, macrophage polarization (stimulation of M1 immunostimulatory macrophages) and activation of $CD8^+$ cytotoxic T cells. This enhanced the efficacy of anti-PD-1 antibody and cancer vaccine immunotherapies. Therefore, manganese nanoparticles can act as anti-proliferative, anti-metastatic, anti-angiogenic, anti-immunosuppressive and tumor-based MRI agents.¹⁴¹

6.3. Antimicrobial activity

Antibacterial activity. Microbial infections are considered to be one of the leading causes of mortality and morbidity globally.^{95,142–144} Different strains of bacteria, fungi, protozoans and viruses are responsible for eliciting infections in human beings. The conventional treatment strategies available such as antibiotics have limitations such as increased antibiotic resistance by microbial strains. Thus, to overcome the limitations of available therapies, metal nanoparticles have been considered. Manganese nanoparticles are reported to exhibit good antimicrobial properties (antibacterial and anti-fungal), and hence are being widely considered and explored.^{95,142,143} For example, Azhir *et al.* designed and synthesized Mn_3O_4 nanoparticles (size range: ~ 10 – 30 nm) through precipitation methods.¹⁴³ The nanoparticles exhibited efficient antibacterial activity against both Gram positive and Gram negative bacteria, which was validated through the broth microdilution method.¹⁴³ In another work, Kamran *et al.* syn-

thesized manganese nanoparticles using *Cinnamomum verum* bark extract and evaluated their antimicrobial activity on *Escherichia coli* and *Staphylococcus aureus*.¹⁴² The natural compounds present in the bark helped in the synthesis of manganese nanoforms and produced effective antimicrobial activity against the above-mentioned strains.

Dual role as antibacterial and antifungal agent. Some manganese nanoforms exhibit both antibacterial and antifungal activity. In this context, Jayandran *et al.* biosynthesized Mn nanoparticles *via* the reduction of manganese acetate with turmeric, curcumin and lemon methanolic extract, exhibiting antibacterial and antifungal activity.⁹⁵ The antibacterial activity of the nanoconjugates was studied against two Gram negative (*Escherichia coli* and *Staphylococcus bacillus*) and Gram positive (*Staphylococcus aureus* and *Bacillus subtilis*) bacteria and the results were compared with free curcumin-treated samples and a positive control experiment (chloramphenicol). Furthermore, the nanoparticles exhibited antifungal activity against four strains of fungi (*Curvularia lunata*, *Candida albicans*, *Trichophyton simii* and *Aspergillus niger*) with Fluconazole drug as the positive control. Therefore, the results clearly suggest the antibacterial and antifungal activity of the biosynthesized Mn nanoparticles.⁹⁵ Among the methods for treating microbial infections, antimicrobial peptides are preferably used. However, the disadvantages associated with them include the cost of their production, stability and toxicity. Hence, to overcome all these issues and increase their efficiency, antimicrobial peptides are conjugated with various nanoparticles. For example, Lopez-Abarrategui *et al.* fabricated and synthesized manganese ferrite nanoparticles (modified with citric acid) with an antifungal peptide obtained from *Cenchrithis muricatus* (sea animal).²⁸ The nanoparticles exhibited excellent *in vitro* antifungal activity against *Candida albicans*. Thus, antifungal peptide-conjugated manganese nanoparticles can be used as an antifungal agent in the near future.²⁸ In another report, Krishnan *et al.* intercalated manganese oxide on bentonite clay using thermal decomposition.¹⁴⁵ The well diffusion and potato dextrose methods were used to study the antifungal and antibacterial activity of the manganese oxide–bentonite nanoconjugates. The antimicrobial activity of these conjugates against *Staphylococcus aureus* was found to be greater compared to *Pseudomonas aeruginosa*. Rapid antifungal behavior was also found against *Candida albicans*.¹⁴⁵

Antiviral activity. Metal nanoparticles have been recently explored as antiviral agents due to their unique properties such as large surface-to-volume ratio and small size to interact with the viral particles.^{146,147} Manganese has been reported to affect AIDS-related pathogens. For example, Nesterenko *et al.* reported the interaction between the AIDS-related pathogen, *Cryptosporidium parvum*, with human ileoadenocarcinoma (HCT-8) cells *in vitro*.¹⁴⁸ The Mn from the MnSO_4 salt inhibited the binding of the sporozoite membrane antigens to the HCT cells, thereby preventing the cells from being infected. These types of interactions are Mn sensitive. Mn^{2+} affects both the pathogen and cell membrane. The possible mechanism

behind this type of interaction is that Mn activates the host cell surface enzymes, which affect the interactions of receptors and ligands.¹⁴⁸ In another work, Vartanian *et al.* demonstrated that Mn enhanced the misincorporation of deoxynucleotide triphosphates (dNTPs) and altered the substrate specificity. Mn caused more mutation of HIV *ex vivo*.¹⁴⁹ Considering the antiviral properties of Mn-salts, we strongly believe that Mn-based nanoparticles can be useful for the treatment of viruses in the near future due to their antiviral activity.

6.4. Antioxidants

Antioxidants are regarded as substances that protect cells from the harmful effects of excessive ROS.^{119,150,151} However, the disadvantages of natural antioxidants such as sensitivity to temperature, short life span and bioavailability have led to the development of artificial ROS scavengers including nanoparticles. Some nanoparticles such as manganese nanoforms owing to their multi oxidation states exhibit antioxidant-like activity for scavenging ROS.^{119,150,151} Accordingly, Singh *et al.* designed Mn_3O_4 nanoparticles for scavenging ROS to prevent oxidative damage of cells.¹¹⁹ They prevented cellular biomolecules from DNA damage, lipid peroxidation and protein oxidation due to the action of ROS. The overall nanosystem can help to suppress oxidative stress-mediated pathological conditions, as shown by the schematic representation in Fig. 4.¹¹⁹ In another report, Yao *et al.* exhibited the antioxidant activity of Mn_3O_4 nanoparticles, which mimicked certain enzyme-like activities such as catalase, superoxide dismutase and hydroxyl radical scavenging actions.⁸² The nanoparticles were effective in scavenging ROS and their by-products *in vitro* and even *in vivo* by ameliorating ROS-induced ear inflammation in a mouse model. Thus, nanoparticles can pave new ways for the treatment of ROS-related diseases.⁸² In another study, Mahlangeni *et al.* biosynthesized manganese oxide nanoparticles using extracts of *Cussonia zuluensis*, which exhibited efficient antioxidant activity. The capping of the metal core with biomolecules of plant extracts enhanced its antioxidant activities.¹⁵⁰

Pardhiya *et al.* demonstrated the *in vitro* antioxidant activity of BSA-templated MnO_2 nanoparticles in human embryonic




Fig. 4 Schematic representation of the molecular mechanism of nano-systems in suppressing oxidative stress-mediated pathological conditions. Reprinted with permission from ref. 119 Singh *et al.*, *Nanoscale*, 2019, 11, 3855–3863. Copyright©2019, The Royal Society of Chemistry.

kidney cells (HEK-293).¹⁵¹ These nanoparticles act in a similar manner to the antioxidant activity of catalase, superoxide dismutase, and peroxidase and were found to increase the viability of the HEK-293 cells. At a higher concentration, these nanoparticles acted like a prooxidant, becoming toxic to normal cells due to their inherent oxidase like activity.¹⁵¹

6.5. Nanozymes

Nanozymes are nanomaterials possessing enzyme-like features including substrate specificity, numerous active sites, enhanced catalytic activity, easy synthesis, low production cost and high efficiency.^{34,118,120,121} The catalytic actions of nanozymes in various microenvironments are controlled by temperature, pH, amount of glutathione, H₂O₂ and oxygenation levels.³⁴ MnO₂ nanoforms are referred to as nanozymes because of their oxidase-like feature. Considering these facts, Liu *et al.* tested the oxidase-like catalytic activity of BSA-based MnO₂ nanoparticles using horseradish peroxidase (HRP) substrates [3,3',5,5'-tetramethylbenzidine (TMB) and *o*-phenylenediamine (OPD)].¹¹⁸ The nanoparticles showed good Michaelis-Menten kinetics together with strong affinity towards HRP substrates and H₂O₂. The nanoforms resulted in the oxidation of the TMB from a pale yellow to blue compound (ox-TMB). The BSA-MnO₂ nanoparticles were soluble, biocompatible in nature and exhibited a good dispersion. The enzymatic property of the BSA-MnO₂ nanoparticles was used to detect goat anti-human IgG for colorimetric immunoassay instead of HRP. Thus, nanoparticles can be used for different bioassays and medicinal purposes in the future.¹¹⁸ Similarly, another colorimetric test assay was developed by Liu *et al.* to check the activity of MnO₂ nanoforms for detecting and quantifying GSH.¹²⁰ GSH inhibited the oxidation of TMB from a pale yellow to blue compound (ox-TMB) by MnO₂ nanosheets in a concentration-dependent manner. This increased specificity of GSH inhibition led to its detection in human serum samples by the nanosystem.¹²⁰

There are reports of manganese nanoparticles being used as DNA partzymes. Usually, the degradation of probes and biomarkers results in false positive test results. Thereafter, to protect both the target and probe, Chen *et al.* synthesized MnO₂ nanoform-powered Janus DNA nanomachines (target- and probe-protective) for RNA imaging.¹²¹ The nanosystem was formed inside living cells *via* the congregation of two DNA partzymes, which are RNA responsive and a probe. The manganese nanoparticles were used both as promoters responsible for DNA cellular uptake and Mn²⁺ generators acting as cofactors of DNAzyme. This ensured the efficacy of catalytic cleavage. The RNA of the RNA-DNA hybrid was protected from degradation by RNase H with the help of the chemically modified DNA partzymes (having modified sugar moieties). The protection of RNA prevented the degradation of the target, resulting in the inhibition of false positive results. Fig. 5 illustrates the design and programming of the Janus nanomachine, where the cellular-RNA target, miR-21, is a green sequence. The chemical structures of DNA, PS-DNA, 2'OMe-DNA, and LNA are represented as a red circle within the gray sequences




Fig. 5 Design and programming of the protective Janus DNA nanomachine. The model cellular-RNA target (green sequence) is miR-21. The chemical structures of a DNA, PS-DNA, 2'OMe-DNA, and LNA monomer are presented, which are highlighted as red circles (red X) in the DNA partzymes (gray sequences). The gray and green circles in the PS-modified substrate probe (blue sequence) are the quencher and fluorophore, respectively. Reprinted with permission from ref. 121 Chen *et al.*, *Anal. Chem.*, 2018, **90**, 2271–2276. Copyright©2018, the American Chemical Society.

of the DNA partzymes. Within the blue sequence of the PS-modified substrate probe are the quencher (gray circles) and fluorophore (green circles). The MnO₂ nanoform-powered Janus DNA nanomachine was beneficial for efficient RNA imaging.¹²¹ In another study, Singh *et al.* demonstrated the morphology-dependent multienzyme redox activity of manganese-based nanozymes (Mn₃O₄).⁶¹ The effect of the Mn₃O₄ nanozymes depended on the size, surface area, morphology and redox property of the manganese ions, which were found to mimic the activity of redox enzymes such as catalase, glutathione peroxidase and superoxide dismutase. The Mn₃O₄ nanoflowers limited the available superoxide levels inside the endothelial cells, thereby preventing the inactivation of nitric oxide (NO), which is essential in the treatment of cardiovascular diseases.⁶¹

6.6. Photothermal and photodynamic therapy

Photothermal therapy is a selective, simple, non-invasive cancer treatment approach, in which near infrared light is used to produce hyperthermia in cancer cells selectively without affecting the surrounding tissue due to the specificity of the PTT agent and NIR light.^{152–156} Photodynamic therapy is defined as a non-invasive cancer treatment strategy in which photosensitizers are used together with light irradiation. In the presence of light and oxygen, the photosensitizers are activated to generate reactive oxygen species and singlet oxygen to kill cancer cells.^{27,152–156} Consequently, this initiates apoptosis and necrosis, thereby killing cancer cells. However, there are still certain limitations of photothermal therapy. Firstly, the hindrance of photothermal therapy due to the hypoxic condition of the tumor microenvironment. Secondly, the non-specificity of photosensitizers in photodynamic therapy causes their premature leakage into normal cells rather than the tumor cells, causing phototoxicity. Thus, to increase the speci-

ficity and functionality of photothermal and photodynamic therapy, they are used in combination with certain nanomaterials to increase their efficiency. Manganese dioxide nanoforms have oxidizing features and help in alleviating the hypoxic condition of the tumor microenvironment by the reaction with the H_2O_2 present within tumors.^{27,152–156} The Mn^{2+} ions produced after the reaction are biocompatible in nature and can be easily excreted through the kidneys. Accordingly, Zhu *et al.* synthesized MnO_2 nanoparticles loaded with a chlorine e6 sensitizer (Ce_6) conjugate followed by PEG coating for the enhancement of tumor-associated photodynamic therapy.¹⁵³ The *in vitro* assays revealed that the Ce_6 @ MnO_2 -PEG nanoparticles reacted with the H_2O_2 present in the cancer cells, thus generating O_2 . This alleviated the tumor hypoxic conditions, increasing the efficiency of photodynamic therapy killing the cancer cells. The *in vivo* results also corroborated the *in vitro* results, where the nanoparticles when injected in mice accumulated within the tumor. Here, the MnO_2 nanoparticles slowly decomposed into Mn^{2+} ions, acting as a T1 MR contrast agent. Overall, the manganese nanoforms increased the oxygen content within the tumor environment to prevent the limitation of hypoxic condition faced by photodynamic cancer therapy.¹⁵³

The untimely release of photosensitizers from their carriers and their non-specific accumulation in normal tissues instead of tumor tissues are major concerns associated with photodynamic therapy. Thus, to alleviate these issues, Ma *et al.* synthesized an MnO_2 shell that can act as a switchable shield for the advancement of acidic H_2O_2 response together with the evolution of O_2 for photodynamic therapy.¹⁵⁵ The development of the nanoplatform proceeded by first loading the core with SiO_2 -methylene blue, which has a high photosensitizer capacity, followed by coating with the MnO_2 shell. This was done to prevent the leakage of the photosensitizer after being intravenously injected into blood before reaching the tumor tissues. This led to the efficient accumulation of the photosensitizer in the tumor tissues. The MnO_2 shell in the acidic tumor microenvironment reacted with H_2O_2 , producing O_2 and achieving a synergistic effect for photodynamic therapy with a decrease in tumor hypoxia. The reduced form of manganese even acts as an MRI imaging agent *in vivo* in the presence of high acidic H_2O_2 .¹⁵⁵ For photothermal therapy, Peng *et al.* constructed erythrocyte membrane-coated Prussian blue/manganese dioxide nanoparticles (PBMn-DOX@RBC) with a red blood cell (RBC) coating for relieving tumor hypoxia and enhancing cancer photothermal therapy and chemotherapy.¹⁵⁶ The PBMn nanoparticles acted as an oxygen precursor or catalyzer for activating H_2O_2 , whereas the RBC membrane increased the loading and prolonged the circulation capacity of doxorubicin (DOX) *in vivo*. In the presence of excess H_2O_2 , administration of the nanoconjugates relieved the hypoxia condition in the tumor microenvironment. The O_2 disrupted the RBC membrane on the nanoformulation, releasing doxorubicin and prolonging the circulation of the nanoparticles in the body. Fig. 6a depicts the photoacoustic images (PA) of the PBMn-DOX@RBC nanoparticles and Fig. 6b shows that the PA



Fig. 6 Photoacoustic imaging (PAI) (A) and PA intensity (MSOT) (B) mediated by PBMn and PBMn-DOX@RBC. The images represent the transverse sections of the mice during photoacoustic imaging. The tumors are marked in red circles. (C) and (D) Photo-thermal conversion of PBMn and PBMn-DOX@RBC *in vivo*, respectively: (C) infrared thermal images of the mice during 808 nm laser irradiation and (D) surface temperatures of the tumor during irradiation. (E) Representative immunofluorescence images of tumor sections stained with DAPI and a hypoxia marker (Hypoxyprobe-1 Kit). Reprinted with permission from ref. 156 Peng *et al.*, *ACS Appl. Mater. Interfaces*, 2017, 9, 44410–44422. Copyright©2017, the American Chemical Society.

signal from the tumors was greater with the PBMn-DOX@RBC nanoparticles than only PBMn. The infrared thermal images of the tumors in Fig. 6c following irradiation with 808 nm show more heat generation from the PBMn-DOX@RBC nanoparticle-treated mice. Subsequently, the temperature of the tumors treated with the PBMn-DOX@RBC nanoparticles also increased more compared to PBMn alone (Fig. 6d). Fig. 6e illustrates the immunofluorescence staining, which shows that the hypoxic condition of the tumor was relieved with the PBMn-DOX@RBC nanoparticles. Therefore, PBMn-DOX@RBC enhanced tumor reduction *via* its combined effect as a chemotherapeutic agent and photothermal therapy agent.¹⁵⁶

Some of the current reports show the use of biomolecules such as proteins for the production of bio-organic nanoparticles. Accordingly, Wang *et al.* synthesized MnO_2 nanoparticles with the help of bovine serum albumin (BSA), which acted as a reducing agent and template for the formation of the nanoparticles.¹⁵² The biocompatible MnO_2 nanoparticles exhibited absorbance in the NIR region and possessed high

photothermal efficiency and stability. Thus, the nanoparticles could be used as an effective NIR photothermal antitumor agent.¹⁵² Liu *et al.* synthesized cobalt/manganese oxide nanocrystals through a hydrothermal process, which exhibited strong NIR absorption and were utilized for photothermal therapy.¹⁵⁷ Also, they were employed for MR imaging *in vivo*. Being biocompatible in nature, the nanocrystals can be used as a potential agent for photothermal theragnosis.¹⁵⁷ Similarly, Cheng *et al.*, studied the magnetic resonance (MR) imaging-guided photothermal therapy of polydopamine-coated manganese carbonate nanoparticles ($\text{MnCO}_3\text{@PDA}$ NPs).¹⁵⁸ The PDA-decorated nanoparticles had excellent MR contrast compared to the free nanoparticles due to the entrapment of more water surrounding the nanoparticles, resulting in water exchange and efficient MR contrast signals. Intratumoral injection of nanoparticles into 4T1 tumor-bearing mice produced efficient MRI-guided photothermal reduction of the tumors, making the nanoparticles excellent theranostic agents.¹⁵⁸ Further, Sun *et al.* designed and synthesized folate receptor nanopalladium-decorated manganese dioxide nanosheets (Fp-Pd@MnO_2) with a high doxorubicin loading capacity.¹⁵⁹ Several factors such as near infrared stimulus, increasing concentration of glutathione and pH reduction are responsible for efficient drug release at the tumor location. Treatment of these nanoparticles with NIR irradiation (808 nm laser) resulted in a combined photothermal and chemotherapy effect in MDA-MB-231 cells along with *in vivo* reduction of the tumor.¹⁵⁹ Considering bimodal application, Gupta *et al.* demonstrated the photothermal and magnetic hyperthermia therapeutic effect of citrate-coated manganese-doped magnetic nanoclusters on a glioblastoma cancer model using rat C6 glioblastoma cells.²⁹ Fig. 7 depicts an overall schematic representation of the combinatorial approach of photothermal and magnetic hyperthermia in killing the glioma cells. When the tumor cells were irradiated with 750 nm laser irradiation, structural changes, cytoskeletal damage, and oxidative stress corresponding to mitochondrial membrane potential reduction occurred, producing ROS-mediated apoptotic cell death.²⁹

6.7. Fluorescence quenchers and biosensors

Fluorescence resonance energy transfer (FRET) is a process describing nonradiative energy transfer from a donor (luminescent) to another molecule (acceptor) in proximity to it through dipole-dipole coupling. FRET technology is used for various applications such as microscopy, immunoassays, and nucleic acid hybridization.^{32,160–163} Recently, 2D nanoforms of manganese with light harvesting features and ability to conduct electrons have been shown to have potential applications in photo-induced sensing (chemical and biological) transfer mechanisms, fluorescence resonance energy transfer (FRET), *etc.* MnO_2 nanosheets exhibit an intense broad absorption peak in the NIR region and manganese, being an ultra-thin semiconductor, facilitates their use as an efficient broad-spectrum quencher.^{32,160} There are reports illustrating that MnO_2 reduction to Mn^{2+} reverses the MnO_2 -associated



Fig. 7 Schematic representation of the combinatorial approach of photothermal and magnetic hyperthermia in killing glioma cells. Reprinted with permission from ref. 29 Gupta *et al.*, *ACS Appl. Nano Mater.*, 2020, 3, 2026–2037. Copyright©2020, the American Chemical Society.

quenching influence and restores the fluorescence of the associated compound.^{32,160} It has been seen that on decreasing the distance between manganese nanoforms and carbon dots, FRET occurs, resulting in the temporary disappearance of the fluorescence of the carbon dots. Based on this, Qu *et al.* synthesized fluorescent carbon dots from the seed extracts of *Sterculia lychnophora*, which were quenched by MnO_2 nanosheets and used as probes for the detection of alkaline phosphatase (ALP).³² The detection occurs by hydrolysis of acidic phosphoric acid (AAP) to ascorbic acid (AA) by ALP, and then AA reduces MnO_2 to Mn^{2+} . Following the destruction of the MnO_2 nanosheets, the fluorescence of the carbon dots was restored. The detection could be performed even at lowest concentrations of ALP, and hence the nanocomplex could be efficiently used for diagnostic purposes.³² In this context, Ji *et al.* designed a $\text{CaO}_2/\text{MnO}_2\text{@polydopamine-methylene blue}$ (MB) nanoform encapsulating CaO_2 nanoparticles with the MnO_2 nanosheets.¹⁶¹ MnO_2 suppressed the fluorescence activity of the MB photosensitizer by π - π stacking or hydrophobic interaction. The nanosystem even had the ability to generate oxygen and alleviate tumor hypoxia. Once in the tumor microenvironment, MnO_2 decomposed to Mn^{2+} , releasing MB and initiating the fluorescence property. In this way, the nanoform was beneficial for both switch-controlled cell imaging and photothermal therapy.¹⁶¹ Because of the catalytic and oxidation activity of manganese nanoparticles, they are extensively used as biosensors. In another work, Yuan *et al.* fabricated an MnO_2 nanosheet-modified upconversion (UC) nanostructure for the fluorescence detection of glucose in the serum and blood of humans.¹⁶⁴ The manganese nanoparticles act as quenchers of the upconversion nanoparticles, which is

relieved once H_2O_2 reduces MnO_2 to Mn^{2+} . The amount of H_2O_2 generated by enzymatic cleavage of glucose using glucose oxidase can be used to detect glucose. This nano-system can be even exploited to identify other H_2O_2 -based analytes.¹⁶⁴

MnO_2 nanoparticles have been further used for the detection of RNAs even at a minute concentration, given that the detection of microRNAs is very challenging owing to their low concentration, similar sequences and small size. Thus, Li *et al.* synthesized an MnO_2 nanosheet-dependent hybridization chain reaction (HCR) system to detect the expression of miRNA inside cells at a low concentration.¹⁶² This is a cell signal amplification-based approach for the detection of miRNAs (which are down regulated), where the MnO_2 nanoparticles quench the dye-labeled hairpin probes. They designed a dual labeled hairpin with FAM (a FRET donor) together with Tamra (TMR, a FRET acceptor) and loaded it on the MnO_2 nanosheets. Once inside the cell, the dye-labeled hairpins were released due to the degradation of the MnO_2 nanosheets by the GSH following reactions with proteins and nucleic acids. Subsequently, miRNA-21 produced dsDNA polymers *via* the cascade assembly of the two hairpins. Consequently, the FRET pair (FAM and TMR) comes into close contact, resulting in enhanced fluorescence signals for detecting miRNA-21 found in trace amounts. Therefore, the nano-system can be used for the detection of trace miRNAs that are found in low concentration in living cells.¹⁶²

6.8. Bioimaging and MRI contrast agents

Magnetic resonance imaging (MRI) works on the principle that many atomic nuclei in the presence of an external magnetic field absorb and emit radiofrequency energy. To increase the radiofrequency signals, hydrogen atoms are used, which are then received by the antenna from the tissues for examination. The advantages of the use of MRI include high spatial resolution, but a disadvantage associated with it is its low sensitivity. Therefore, manganese nanoforms are being used as alternative contrast agents for T_1 -weighted MRI, given that they are biocompatible, help in achieving brighter images, have short circulation time of Mn^{2+} ion chelate, and size-directed circulation time of colloidal nanoforms.^{26,27,165–167} The underlying mechanism is that the manganese atoms located within the manganese nanosheets make no contact with the external aqueous environment, thus preventing the transverse and longitudinal relaxation of protons. The various forms manganese nanoparticles (MnO , Mn_3O_4 , and MnO_2) are used as contrast agents in MRI, bimodal and multimodal imaging and imaging-guided tumor therapy. For T_1 -weighted MRI, Wang *et al.* designed and synthesized L-cysteine and PEG-modified manganese oxide NPs *via* a solvothermal process.⁸ The as-synthesized nanoparticles exhibited good T_1 -relaxivity, increased solution dispersibility, biocompatibility and colloidal stability. The modification with L-cysteine increased the blood circulation time with the reduction of cellular uptake by macrophages, thereby making the nanoparticles good contrast agents for enhancing T_1 -weighted MRI.⁸

Some manganese-coated nanoparticles are conjugated with aptamers to enhance their tumor-specific targeting ability. For example, Li *et al.* synthesized biocompatible PEG-coated MnO nanoparticles conjugated with a covalently cross-linked aptamer as contrast agents for T_1 -weighted MRI.¹⁶⁸ These nanoparticles targeted renal cancer tumor cells together with prolonged storage of the probe within the tumor cells.¹⁶⁸ To achieve enhanced imaging for clinical demands, PET and MRI dual-mode imaging is used through the development of PET/ T_1 -MRI bimodal mode probes. In this context, Zhu *et al.* developed PET/MRI bimodal probes *via* the surface modification of PEI-coated Mn_3O_4 nanoparticles with Cu^{64} and folic acid (FA).¹⁶⁹ The as-synthesized nanoprobles were injected in HeLa tumors with both blocked and unblocked folate receptors, and it was observed that the Cu^{64} -labeled nanoparticles acted as better tracers in the non-blocked HeLa tumors even after 18 h of injection. Fig. 8 shows the micro PET images of the xenografted HeLa tumor-bearing nude mice treated with the nanoparticles, where the PEI-coated Mn_3O_4 nanoparticles with Cu^{64} and folic acid showed the maximum uptake.¹⁶⁹ In another work, Zhan *et al.* synthesized and developed Mn_3O_4 nanoparticles that were conjugated with radionuclide copper-64 (^{64}Cu) and anti-CD105 antibody, which helped in the targeted imaging of the tumor vasculature in mice.¹⁷⁰ The nanocomplex exhibited stability in both *in vivo* and *in vitro*. The biodistribution study showed the targeted accumulation of the manganese nanocomplex within the breast tumor of the mice and its specificity was further confirmed. Fig. 9 shows the serial PET scan images of the Mn_3O_4 -radionuclide copper-64 (^{64}Cu)-TRC105 (targeted), Mn_3O_4 -radionuclide copper-64 (^{64}Cu) (non-targeted) and Mn_3O_4 -radionuclide copper-64 (^{64}Cu)-TRC105 with pre-incubated blocking using TRC105. Therefore, this elucidates that the manganese




Fig. 8 MicroPET images of nude mice bearing HeLa xenografted tumors at different time points post-intravenous injection of the ^{64}Cu -NOTA-FA-FI-PEG-PEI-Ac- Mn_3O_4 NPs (targeted NPs), ^{64}Cu -NOTA-FA-FI-PEG-PEI-Ac- Mn_3O_4 NPs with FA blocking, and ^{64}Cu -NOTA-FI-PEG-PEI-Ac- Mn_3O_4 NPs (nontargeted NPs). The whole-body coronal (top) and transverse (bottom) microPET images of nude mice bearing HeLa xenografted tumors are shown. Tumors are indicated by arrows. Reprinted with permission from ref. 169 Zhu *et al.*, *ACS Appl. Mater. Interfaces*, 2018, 10, 34954–34964. Copyright©2018, the American Chemical Society.




Fig. 9 Serial coronal PET images of 4T1 tumor-bearing mice after injection of ^{64}Cu -NOTA- Mn_3O_4 @PEG-TRC105, ^{64}Cu -NOTA- Mn_3O_4 @PEG, or ^{64}Cu -NOTA- Mn_3O_4 @PEG-TRC105 after a pre-injected blocking dose of TRC105. Arrowheads indicate tumor locations. Reprinted with permission from ref. 170 Zhan *et al.*, *ACS Appl. Mater. Interfaces*, 2017, 9, 38304–38312. Copyright©2017, the American Chemical Society.

nanocomplex can be efficiently used as potent T1 contrast agents for cancer diagnosis.¹⁷⁰

6.9. Mechanism of action of manganese-based nanoparticles

Manganese-based nanoparticles are emerging as new-age agents for biomedical applications in the area of transition metal nanoparticles. All their applications such as drug delivery, photothermal therapy, antimicrobial, and anti-angiogenic have different mechanisms of action.^{27,118,119,141} Manganese nanoparticles are readily used for drug delivery applications due to their large surface to volume ratio, biocompatibility, non-toxicity and efficient targeted delivery, increasing their sensitivity towards the tumor microenvironment.²⁷ The nanoforms of manganese oxide even have oxidase-like feature, and hence are referred to as nanozymes.¹¹⁸ This feature of manganese nanoparticles together with their multi oxidation states helps them to act like antioxidants and scavenge ROS.¹¹⁹ Manganese has a tendency to alleviate hypoxia, leading to an anti-tumor and anti-angiogenic effect for assisting cancer therapeutics.¹⁴¹ Further, manganese nanoparticles exhibit good antimicrobial properties (antibacterial and antifungal).^{142,143}

For photothermal therapy, manganese nanoforms exhibit oxidizing properties for alleviating the hypoxic condition by interaction with H_2O_2 , producing O_2 in the tumor microenvironment.²⁷ This also prevents the limitation faced by photothermal cancer therapy due to the hypoxic condition of the tumor microenvironment.¹⁵³ Manganese nanoforms act as a shell to prevent leakage of photosensitizers, where the photosensitizers accumulate within the tumors during photodynamic therapy.¹⁵⁵ Also, manganese-based nanoparticles are slowly decomposed into Mn^{2+} ions, helping them to be T1 MR contrast agents.¹⁵³ Besides photothermal and photodynamic therapy, manganese nanoforms are efficient as fluorescence quenchers and biosensors. The 2D manganese nanoforms have light harvesting properties and conduct electrons, which

are used for sensing (chemical and biological) in photo-induced transfer mechanisms, fluorescence resonance energy transfer (FRET), *etc.* Manganese nanosheets exhibit a broad absorption peak in the NIR region. Considering that Mn is an ultrathin semiconductor, it facilitates its use as a good broad-spectrum quencher. The reduction of MnO_2 to Mn^{2+} reverses the MnO_2 -associated quenching influence and restores the fluorescence of the associated compound.³² For example, manganese nanoparticles can act as quenchers of upconversion nanoparticles, which is relieved once H_2O_2 reduces MnO_2 to Mn^{2+} .¹⁶⁴ Therefore, all these mechanisms elucidate the role of manganese nanoforms for future biomedical applications.

7. Other applications of manganese nanoparticles

Besides the biomedical applications of manganese nanoparticles, they have various other uses, as reported in the literature.^{171–175} As mentioned in the previous sections regarding the role of Mn in living systems, Mn nanoparticles are used as nutritional supplements. They have been used for reproduction, skeletal abnormalities, growth, *etc.* for all living animals. Mn nanoparticles are readily used as aquatic food supplements. For example, Asaikkutti *et al.* developed biosynthesized Mn_3O_4 nanoparticles as supplements in the diet of freshwater prawn *Macrobrachium rosenbergii*.¹⁷¹ The Mn supplements increased the metabolism and antioxidant systems of the prawns, which in turn enhanced their growth and survival.¹⁷¹

Manganese-based nanoforms have been reported to show good electrochemical efficiency and used in lithium-ion batteries together with supercapacitors.^{172–174} For example, Chen *et al.* developed a composite containing graphene oxide-manganese oxide nanocrystals, exhibiting electrochemical behavior, and therefore can be used as electrodes for different devices, catalysis reactions and as adsorbents.¹⁷² Some reports in the literature regarding manganese nanoparticles exhibited their optical and magnetic properties.¹⁷⁶ For example, Djerdj *et al.* demonstrated the ferromagnetic property of manganese nanoparticles using squid analysis.¹⁷⁶ Biswas *et al.* synthesized manganese-incorporated ZnS nanorods having orange luminescence and broad Lorentzian-shaped EPR spectra (with emissions in the blue, orange and green regions) for emissive device magnetic dipole interaction.¹⁷⁷ It is known that the paper and textile industries release a huge amount of non-degradable dye as natural carcinogens and environmental pollutants. In some reports, manganese-based nanoparticles have been shown to have degradation ability for dyes (safranin O and Congo red).¹⁷⁵ Manganese has even been used for water purification. The toxic forms of arsenic are considered major water pollutants, which are responsible for hyperpigmentation, circulatory disorders, and skin and liver cancer. For example, Bajpai *et al.* developed manganese dioxide-coated sand, which helped in the removal of arsenic contamination from water bodies.¹⁷⁸ Similarly, Camacho *et al.* illustrated that manganese dioxide modified with clinoptilolite-Ca zeolite removed

arsenic from groundwater.¹⁷⁹ In the presence of cerium ammonium nitrate and hydrogen peroxide, manganese oxide nanoparticles possess good catalytic property for water oxidation and epoxidation of olefins. These compounds also perform epoxidation of aromatic and non-aromatic olefins in the presence of bicarbonate ions and H₂O₂.¹⁸⁰

Besides, manganese nanoparticles have a huge impact in agricultural applications including crop growth and ease from abiotic stress, rendering the lowest toxicity compared to their ionic and bulk counterparts.¹⁸¹ Nano metal oxide manganese (NMO-Mn) plays a scavenging role and has been utilized as sorbents and fertilizers to increase the yield of crops. In agricultural systems, Mn immobilized soil contaminants to increase the crop health in staple foods such as wheat, rice, soybean, and maize.¹⁸² Accordingly, Ye *et al.* investigated the ability of manganese oxide nanoparticles to reduce salinity stress in *Capsicum annuum* to improve stress management in agricultural yield.¹⁸³ Pradhan *et al.* studied the detailed biophysical, biochemical and molecular mechanism of manganese nanoparticles on *Vigna radiata* (mung bean, a leguminous plant).¹⁸⁴ The manganese nanoparticles did not impart any toxicity towards the mung bean plant compared to manganese sul-

phate, which is a commercially available manganese salt. Based on the results, it was concluded that these nanoparticles can be used as a biosafe micronutrient and nanomodulator in the agricultural sector.¹⁸⁴ Further, Pradhan *et al.* investigated the role of nano Mn in non-nodulated plants. They found that nano Mn increased nitrogen assimilation, uptake and metabolism compared to the commercially available Mn sulphate salt.¹⁸⁵

Table 2 presents the different biological applications of manganese-based nanoparticles.^{8,29,32,61,82,95,118–122,131–135,140–143,145,150–153,155–159,161,164,168–171}

8. An update of the toxicological evaluation of manganese nanoparticles

Nanomaterials have emerged as the leading candidates for several biomedical applications. Thus, for their future clinical implications, the toxicity of different nanomaterials should be evaluated.¹⁸⁶ The extensive utilization of manganese nanoparticles for various biomedical applications calls for their tox-

Table 2 Biological applications of manganese nanoparticles

| Manganese (Mn) conjugates | Biomedical applications | Ref. |
|--|---|-------------|
| MnO ₂ -Fe ₃ O ₄ @SiO ₂ , NaYF ₄ :Yb | Drug carrier, quenchers | 122 |
| MnO ₂ nanosheet-DNAzyme | Gene slicing, bimodal cancer treatment | 131 |
| mMnO ₂ -UCNPs@mSiO ₂ -chlorin e6 | Trimodal imaging, chemo-photodynamic | 132 |
| Mn-CoO-doxorubicin | Anticancer activity | 133 |
| MnFe ₂ O ₄ Np | Drug delivery | 134 |
| MnO ₂ -Au nanorods | Efficient delivery of doxorubicin | 135 |
| Mn nanoparticle | Anti-angiogenesis | 140 |
| MnO ₂ -sorafenib | Treatment of cancer, MRI | 141 |
| Mn ₃ O ₄ nanoparticle | Antibacterial | 143 |
| Mn- <i>Cinnamomum verum</i> bark extract | Antimicrobial activity | 142 |
| Mn-curcumin-lemon methanolic extract | Antibacterial and antifungal activity | 95 |
| Manganese ferrite-citric acid | Antifungal activity | 134 |
| MnO-bentonite clay | Antibacterial and antifungal activity | 145 |
| Mn ₃ O ₄ nanoparticle | Scavenges ROS | 82 |
| MnO extracts of <i>Cussonia zuluensis</i> | Antioxidant activity | 150 |
| MnO ₂ -BSA | <i>In vitro</i> antioxidant activity | 151 |
| MnO ₂ -BSA | Detect goat anti-human IgG | 118 |
| MnO ₂ nanoparticle | Detect and quantify GSH | 120 |
| MnO ₂ -Janus DNA | RNA imaging | 121 |
| MnO ₂ nanozyme | Antioxidant | 119 |
| Mn ₃ O ₄ | Mimics activity of redox enzymes | 61 |
| MnO ₂ | Photothermal therapy | 156 |
| MnO ₂ -chlorine e6 sensitizer (Ce ₆)-PEG | T1 MR contrast agent | 153 |
| MnO ₂ -SiO ₂ -methylene blue | MRI imaging, photothermal therapy | 155 |
| MnO ₂ -BSA | NIR photothermal antitumor therapy | 152 |
| Co/MnO ₂ nanocrystals | MR imaging, antitumor activity | 157 |
| MnCO ₃ @PDA NPs | MR contrast agent, anticancer | 158 |
| Fp-Pd@MnO ₂ | Chemo-photothermal therapy | 159 |
| Citrate-Mn-doped magnetic nanoclusters | ROS mediated photothermal therapy | 29 |
| MnO ₂ - <i>Sterculia lychnophora</i> | Alkaline phosphatase detection | 32 |
| CaO ₂ /MnO ₂ @PDA-MB | Cell imaging, photothermal therapy | 161 |
| UC-MnO ₂ | Fluorescence detection | 164 |
| MnO ₂ nanosheet-HCR | miRNA detection | 133 and 134 |
| MnO-L-cysteine-PEG | Contrast agents for T ₁ weighted MRI | 8 |
| PEG-MnO-aptamer | Dual mode imaging (PET and MRI) | 168 |
| Mn ₃ O ₄ -PEI-Cu ⁶⁴ -folic acid | Bioimaging | 169 |
| Mn ₃ O ₄ - ⁶⁴ Cu-TRC105 | T1 contrast agent | 170 |
| Mn ₃ O ₄ NP | Food technology | 171 |

icity assessment both *in vitro* and *in vivo*.^{160,187} There are reports regarding the toxicity studies of the manganese nanoparticles, both *in vitro* and *in vivo*.^{121,188–190} For example, He *et al.* synthesized manganese dioxide nanosheets-carbon dots with a quenched fluorescent system for sensing glutathione in aqueous solutions.¹⁹¹ The nanocomplex exhibited low cytotoxicity to HeLa cells at a concentration below $30 \mu\text{g mL}^{-1}$ within 24 h.¹⁹¹ Similarly, Yan *et al.* designed and fabricated GQD with manganese nanoforms to exhibit least toxicity towards MCF-7 cell lines at a concentration of $40 \mu\text{g mL}^{-1}$.¹⁹² Manganese nanoparticles have been found to affect neurobehavior and the functions of dopaminergic neurons. For example, Li *et al.* intracerebrally injected manganese nanoforms in the substantia nigra and ventral tegmental area of the brain in Sprague-Dawley rats.¹⁹⁰ The neurological behavior of the rats was evaluated using a Morris water maze test and immunohistochemistry. The results revealed that the escape latencies of the nanoparticle-treated rat increased with respect to the control. Also, the manganese-treated groups exhibited tyrosine hydroxylase (TH)-positive cell reduction with an increase in inducible nitric oxide synthase (iNOS) and glial fibrillary acidic protein (GFAP) positive cells within the lesion side of the rat brains with respect to the contralateral area. Fig. 10 illustrates that the amount of GFAP-positive cells in the damaged side (Fig. 10A and C) is more than that in the contralateral (Fig. 10B and D)

and saline control damaged side (Fig. 10E and F). Therefore, the alteration in the spatial learning techniques of rats in the manganese-treated groups resulted in neuronal dopaminergic dysfunction and activation of astrocytes.¹⁹⁰

There are reports of the clearance of manganese nanoparticles through the renal route. For example, Zhou *et al.* designed and synthesized very small manganese and gallium-doped copper sulphide nanodots with bovine serum albumin (BSA) as a template for triple modal imaging and photothermal therapy.¹⁹³ These imaging systems confirmed that the nanoparticles are efficiently cleared from the body *via* the renal urinary route, thus minimizing their toxicity towards non-tumor organs. Fig. 11 exhibits the renal clearance of the nanoparticles through MR imaging (Fig. 11A) and photoacoustic imaging (Fig. 11B), which shows that the nanoparticles were cleared through the renal route.¹⁹³ In another work, Xu *et al.* synthesized manganese-melanin nanoparticles as MRI contrast agents for *in vivo* tumor targeting.¹⁹⁴ Further, the authors claimed that these nanoparticles were found to be less toxic than the clinically approved MRI agent Gadodiamide. The manganese-melanin nanoparticles were also cleared from the body *via* the hepatobiliary and renal system, proving to be less toxic to the body organs with specific tumor targeting capability.¹⁹⁴ Considering that the application of manganese-based nanoparticles has been increasing recently, their effect




Fig. 10 GFAP immunohistochemical staining of the hippocampus of rats (400 \times , bar = 50 μm). (A) Damaged side, nano-MnO₂ group; (B) uninjured side, nano-MnO₂ group; (C) damaged side, 6-OHDA group; (D) uninjured side, 6-OHDA group; (E) damaged side, saline group; and (F) uninjured side, saline group. Reprinted with permission from ref. 190 Li *et al.*, *Int. J. Environ. Res. Public Health*, 2014, **11**, 7918–7930. Copyright©2014 Li *et al.*




Fig. 11 Renal clearance. (A) *In vivo* MR imaging of mice kidneys before and after intravenous injection of NDs of varying time. Kidneys are indicated by orange arrows. (B) *In vivo* PA imaging of mice kidneys before and after intravenous injection of NDs of varying time. Reprinted with permission from ref. 193 Zhou *et al.*, *Appl. Mater. Today*, 2018, **13**, 285–297. Copyright©2018, Elsevier Ltd. All rights reserved.

on the reproductive health of living organisms is a major concern. Accordingly, Yousefalizadegan *et al.* studied the reproductive toxicity of micro- and nanoforms of manganese dioxide on the spermatogenesis of male Wistar rats.¹⁹⁵ Subcutaneous injection of nano/microparticles of manganese dioxide (100 mg kg⁻¹) reduced the number of spermatocytes, sperms, spermatogonia, motility of sperms and diameter of seminiferous tubule. However, there was no significant effect on the production of testosterone, estradiol hormone and the weight of the epididymis, prostate and left testicle.¹⁹⁵

In a different study, Feng *et al.* investigated the magnetic targeting and tumor microenvironment response of magnetic nanoconjugates with an iron carbide–glucose oxidase–manganese nanoshell.¹⁹⁶ The clearance and toxicity profile of the nanoparticles were studied, which showed that intravenous injection of these nanoparticles into mice resulted in time-dependent clearance (especially through the kidney and liver). The histocompatibility profile had no pathological abnormalities in the liver, spleen, heart, kidney, lung. Also, a low impact was observed on hematological parameters such as mean corpuscular hemoglobin, hemoglobin, red blood cells, and hematocrit value. Also, the biochemical assays showed that the liver enzymes alanine aminotransferase (ALT), alkaline phosphatase (ALP) and aspartate aminotransferase (AST) remained normal, indicating healthy liver function.¹⁹⁶ In another type of work, Zhu *et al.* constructed multifunctional nano-sonosensitizers using mesoporous organosilica integrated with MnO_x nanoparticles conjugated with cyclic arginine–glycine–aspartic pentapeptide (targeting peptide) and protoporphyrin (sonosensitizer).¹⁹⁷ The *in vivo* excretion and biocompatibility of the nanoforms were evaluated. The results revealed no significant difference in the blood indexes (ALT, AST, ALP, red blood cell count, creatinine, white blood cell count, mean corpuscular hemoglobin concentration, *etc.*) and body weight upon intravenous injection with the nanoconjugates in a dose-dependent manner. The hepatochemistry, physiochemistry and serum parameters also indicated that the nanoparticles exhibited no toxicity.¹⁹⁷

Manganese plays a role in the proper functioning of the nervous system through neurotransmitter uptake and release. However, excess manganese can cause neurotoxicity such as Alzheimer's and Parkinson's disease, a common form of dementia (caused by the formation of neurofibrillary tangles) together with rigidity, tremors, and bradykinesia.¹⁹⁸ Imbalanced oxidative stress due to the decreased activity of antioxidant enzymes, induction of nitric oxide synthase in astrocytes, accumulation of inflammatory cytokines and lipid peroxidation mediate Alzheimer's and Parkinson's disease. Accordingly, Tong *et al.* illustrated that a higher concentration of Mn caused increased plasma amyloid beta peptides, leading to Alzheimer's.¹⁹⁹ Excess Mn accumulation leads to a condition called manganism, the phenotypic features of which are analogous to idiopathic Parkinson's disease.²⁰⁰ The Mn-related parkinsonism affects dopaminergic neurons together with monoaminergic neurotransmitters within the basal ganglia and other limbic features.²⁰¹ Mn also plays a secondary role in mitochondrial dysfunction, which is mainly

involved in these neurological diseases.^{202,203} Mn induces misfolding and accumulation of the alpha-synuclein protein, which plays the primary role in the pathology of Parkinson's disease.²⁰⁴ Therefore, an imbalance of oxidative stress and mitochondrial metabolism is involved in Mn-induced neurotoxicity responsible for neurological disorders. Manganese neurotoxicity was first reported in 1937 in a manganese-based bleach manufacturing company, which was the largest hypochlorite bleaching power producer at that time. Also, during the First World War, 9 patients developed neurological impairment in different continental regions of Europe.^{40,205,206}

In an agricultural area, Pradhan *et al.* investigated the *in vitro* and *in vivo* toxicity of manganese nanoparticles for their utilization as micronutrient in nitrate assimilation compared to the commercially utilized manganese sulfate.¹⁸⁵ The manganese nanoparticles were non-toxic to the mice brain mitochondria except for the partial impairment of complex II and III in the electron transport chain, and thus can be used as an alternative nanofertilizer.¹⁸⁵ For the first time, Ghosh *et al.* reported the genotoxic effect of manganese nanoparticles at a high concentration (20 µg mL⁻¹), causing DNA hypomethylation in *Physcomitrella patens* (moss).²⁰⁷ The DNA strand breaks were analyzed *via* the comet assay, showing the generation of reactive oxygen species due to the uptake, internalization and dissolution of manganese.²⁰⁷

9. Future perspective and challenges

The advancement of transition metal nanotechnology involving manganese in the field of biology has paved the way towards advanced therapeutic applications in biomedical science.²⁰⁸ Manganese nanoforms having unique structural and functional features are widely explored for various biomedical and other applications.²⁰⁹ Manganese nanoforms have been readily explored for targeted delivery at specific locations, antimicrobial activities, as nanozymes to prevent damage from oxidative species, photothermal therapy and bioimaging activities.^{27–35}

However, despite their various biomedical applications, there are certain drawbacks or challenges regarding manganese-based nanoparticles, which hamper their further progress in the commercial field.¹⁸⁶ Firstly, the large-scale production of manganese nanoparticles at the industrial level requires the use of a large amount of organic solvents, high temperature reactors, centrifugation, milling, sonication, filtration, *etc.*²¹⁰ A minor change in these reaction-generating conditions can lead to unstable, inactive and undesirable compounds.¹⁸⁶ Secondly, nanoparticles due to their small size have a tendency to target non-specific healthy cells together with tissues.¹⁸⁶ The targeting by nanoparticles should be specific to decrease their non-specific toxic effects. Thirdly, the permeability and diffusion of nanoparticles through the cell barrier are a crucial challenge related to their uptake and efficacy.^{186,211,212} The main blockades related to the intravascular delivery of nanoforms are immune rejection, clearance issues from the liver, spleen and

kidney, permeability in the target organs, receptor-mediated entry into cells, diffusion through the cytoplasm, and nucleus entry.²¹³ Fourthly, the toxicity of nanoparticles needs to be evaluated given that human health risks associated with the increased emergence of nanoforms are a major challenge for their application. Detailed toxicological evaluations are a major part for the use of nanoparticles.^{214,215} Fifthly, the immunogenicity (immune response generated inside the animal by nanoparticles) study should be properly assayed prior to their use as diagnostic and therapeutic agents in the near future.¹²⁴ The biodegradability and clearance of nanoparticles from living systems are a major concern. Liposomal formulations are easily cleared from the body within a short time. However, metal nanoparticles can sometimes exhibit slow metabolic degradation.^{124,186} Besides, manganese nanoparticles also play a significant role (as macro/micro nutrient) in plant growth and metabolism, where their slower release properties reduce the abiotic stress of plants.²¹⁶ However, certain challenges such as their complete mechanisms (plant-nanoparticle interaction, transformation, translocation and transportation studies) are poorly understood. Thus, detailed studies are required for crop stress management to improve the agricultural yield.

Future perspectives towards the development of efficient manganese-based nanoparticles for various biomedical applications involve different factors. During the initial development of manganese nanoparticles on the lab scale, suitable approaches should be considered for their large-scale manufacture, considering the synthesis conditions for a larger yield, better quality and higher efficiency of the nanoparticles.^{124,186} Therefore, factors such as ecofriendly, low cost, biocompatible synthesis, reproducible formulation of the nanoparticle, and characterization are to be tested prior to their commercialization. Also, the production cost should be verified to enter the global market for high quality production strategies. Next the specificity of the nanoparticles should be modified for active targeting using targeting agents such as peptides, integrins, and drugs for increased therapeutic efficacy and less toxic effects.²¹³ Further, the diffusion and entry blockades of nanoparticles should be given the utmost care for their efficient therapeutic ability. The size, shape, charge and other structural and functional parameters should be consistent for proper permeation within target organs. Also, detailed toxicity profile (long-term toxicity study such as bioaccumulation/bio-distribution, dosage, renal clearable properties, metabolism, and pharmacodynamic and pharmacokinetic profiles) and immunological studies need to be evaluated properly by using different animal models prior their FDA approval and clinical application.^{214,217,218} Currently, there are several nanoparticles that are either US FDA approved or undergoing clinical trials. Although most of the nanoformulations that are FDA approved are inclined towards liposomal, polymeric and nanocrystal compounds, there is an increasing trend for the development of protein-based nanoparticles, micelles and inorganic metal nanomaterials for clinical trials.^{219,220} Therefore, Mn nanoparticles will have future opportunity to be FDA approved

drugs for various biomedical applications after their proper bio-safety evaluation in large animals and humans in the future. The earlier discussed Section 8 highlighted several reports of *in vitro* and *in vivo* toxicity studies of manganese-based nanoforms. Moreover, the mechanism behind the biodegradability and clearance of metal nanoparticles is currently considered an active area of nanotechnology research. Considering all the above-mentioned facts, manganese-based nanoparticles hold a promising future in biology, medicine and other industrial sectors.

10. Conclusion

Over the last decade, the use of the manganese-based transition metal nanoparticles has revolutionized theranostics applications in the field of biology through their multifunctional features. Referring to its presence in living systems, manganese is widely applied for drug delivery, as anti-microbial agents, anti-angiogenic agents, enzymes, photothermal agents, fluorescence agents, *etc.* Considering the potential biomedical applications of manganese, the discovery of new, efficient, economically cheap, safe manganese nanomaterials that can be utilized as an alternative treatment strategy for various diseases is urgently required. Therefore, scientists globally are designing new size- and shape-dependent manganese-based nanomaterials by changing the reaction parameters during their synthesis thorough chemical, physical and biological synthetic approaches. Manganese-based nanoforms can be readily utilized in the commercial market in combination with other compounds depending on the advancement stages with optimization and after their proper biosafety evaluation. The other factors including efficacy, metabolic fate, immunogenicity and pharmacokinetic studies should be properly evaluated before their commercial utilization. Considering that manganese offers multiple benefits not only in healthcare but also in the electronics, food, water and textile industries, the current comprehensive review article will attract a wider spectrum of the scientific community (both specialized and non-specialized).

Abbreviations

| | |
|------|-----------------------------------|
| AA | Ascorbic acid |
| AAP | Acidic phosphoric acid |
| ALP | Alkaline phosphatase |
| ALT | Alanine aminotransferase |
| AST | Aspartate aminotransferase |
| ATP | Adenosine triphosphate |
| BSA | Bovine serum albumin |
| CAM | Chorioallantoic membrane assay |
| DNA | Deoxyribonucleic acid |
| DOX | Doxorubicin |
| EDX | Energy dispersive X-ray analysis |
| EELS | Electron energy loss spectroscopy |

| | |
|----------|--|
| FESEM | Field emission scanning electron microscopy |
| FRET | Fluorescence resonance energy transfer |
| GFAP | Glial fibrillary acidic protein |
| GSH | Glutathione |
| GQD | Graphene quantum dots |
| HCC | Hepatocellular carcinoma |
| HDL | High-density lipo-protein |
| HRP | Horseradish peroxidase |
| HRTEM | High resolution transmission electron microscopy |
| iNOS | Inducible nitric oxide synthase |
| MRI | Magnetic resonance imaging |
| NIR | Near infrared |
| NPs | Nanoparticles |
| PDA | Polydopamine |
| PEG | Polyethylene glycol |
| PET | Positron emission tomography |
| PVP | Polyvinylpyrrolidone |
| PS | Photosensitizer |
| Mn | Manganese |
| MnSOD | Manganese superoxide dismutase |
| OPD | <i>o</i> -Phenylenediamine |
| RBC | Red blood cell |
| RDI | Reference daily intake |
| ROS | Reactive oxygen species |
| RNA | Ribonucleic acid |
| SEM | Scanning electron microscopy |
| SQUID | Superconducting quantum interface device |
| TEM | Transmission electron microscopy |
| TH | Tyrosine hydroxylase |
| TMB | Tetramethylbenzidine |
| UC | Upconversion |
| U.S. FDA | U.S. Food and Drug Administration |
| NRC | National Research Council |
| XRD | X-ray diffraction |

Author contributions

The article was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Conflicts of interest

The authors declare no competing financial interest.

Acknowledgements

CRP is grateful to CSIR, New Delhi for generous financial support (HCP0040). We thank the Director of the CSIR - Indian Institute of Chemical Technology (Ms. No. IICT/Pubs./2021/215) for providing all the required facilities to carry out the work. SH and ST are thankful to the CSIR and UGC, New Delhi for supporting their Research Fellowship, respectively.

Notes and references

- N. Pandey, S. Dhiman, T. Srivastava and S. Majumder, *Chem.-Biol. Interact.*, 2016, **254**, 221–230.
- W. Zhao, A. Li, A. Zhang, Y. Zheng and J. Liu, *ChemMedChem*, 2018, **13**, 2134–2149.
- L. Ricciardi and M. La Deda, *SN Appl. Sci.*, 2021, **3**, 372.
- A. D. Karthik and K. Geetha, *Open Access J.*, 2016, **3**, 28–34.
- D. J. Bonda, G. Liu, P. Men, G. Perry, M. A. Smith and X. Zhu, *CNS Neurol. Disord.: Drug Targets*, 2012, **11**, 81–85.
- M. Wu, J. Shi and H. Deng, *Arabian J. Chem.*, 2018, **11**, 924–934.
- T. E. Stevens, C. J. Pearce, C. N. Whitten, R. P. Grant and T. C. Monson, *Sci. Rep.*, 2017, **7**, 44191.
- P. Wang, J. Yang, B. Zhou, Y. Hu, L. Xing, F. Xu, M. Shen, G. Zhang and X. Shi, *ACS Appl. Mater. Interfaces*, 2017, **9**, 47–53.
- A. Ottmann, M. Scholz, M. Haft, E. Thauer, P. Schneider, M. Gellesch, C. Nowka, S. Wurmehl, S. Hampel and R. Klingeler, *Sci. Rep.*, 2017, **7**, 13625.
- Chemistry of the Elements*, ed. N. N. Greenwood and A. Earnshaw, Butterworth-Heinemann, Oxford, 2nd edn, 1997, pp. 1040–1069, DOI: 10.1016/B978-0-7506-3365-9.50030-4.
- D. Wang and D. Astruc, *Chem. Soc. Rev.*, 2017, **46**, 816–854.
- S. K. Ghosh, *ACS Omega*, 2020, **5**, 25493–25504.
- L. H. Madkour, in *Reactive Oxygen Species (ROS), Nanoparticles, and Endoplasmic Reticulum (ER) Stress-Induced Cell Death Mechanisms*, ed. L. H. Madkour, Academic Press, 2020, pp. 81–105, DOI: 10.1016/B978-0-12-822481-6.00004-9.
- B. Alloway, *Heavy Metals and Metalloids as Micronutrients for Plants and Animals*, *Environmental Pollution*, Springer, Dordrecht, 2013, vol. 22, pp. 195–209.
- L. Li and X. Yang, *Oxid. Med. Cell. Longevity*, 2018, **2018**, 7580707–7580707.
- J. L. Aschner and M. Aschner, *Mol. Aspects Med.*, 2005, **26**, 353–362.
- R. A. Beckman, A. S. Mildvan and L. A. Loeb, *Biochemistry*, 1985, **24**, 5810–5817.
- F. C. Wedler, *Prog. Med. Chem.*, 1993, **30**, 89–133.
- L. F. Reichardt and R. B. Kelly, *Annu. Rev. Biochem.*, 1983, **52**, 871–926.
- D. Klimis-Zacas, *Manganese in health and disease*, CRC Press, 1993.
- D. S. Avila, R. L. Puntel and M. Aschner, in *Interrelations between essential metal ions and human diseases*, Springer, 2013, pp. 199–227.
- Icahn School of Medicine at Mount Sinai, <https://icahn.mssm.edu/about/departments/environmental-public-health/divisions/occupational-environmental/manganese>, 2021.
- C. King, M. Myrthil, M. Carroll and E. Catapane, *In Vivo*, 2008, **29**, 26–34.
- J. W. Finley, P. E. Johnson and L. K. Johnson, *Am. J. Clin. Nutr.*, 1994, **60**, 949–955.
- T. R. Guilarte, *Front. Aging Neurosci.*, 2013, **5**, 23.

- 26 X. Cai, Q. Zhu, Y. Zeng, Q. Zeng, X. Chen and Y. Zhan, *Int. J. Nanomed.*, 2019, **14**, 8321–8344.
- 27 Y. Chen, H. Cong, Y. Shen and B. Yu, *Nanotechnology*, 2020, **31**, 202001.
- 28 C. Lopez-Abarrategui, V. Figueroa-Espi, M. B. Lugo-Alvarez, C. D. Pereira, H. Garay, J. A. Barbosa, R. Falcão, L. Jiménez-Hernández, O. Estévez-Hernández, E. Reguera, O. L. Franco, S. C. Dias and A. J. Otero-Gonzalez, *Int. J. Nanomed.*, 2016, **11**, 3849–3857.
- 29 R. Gupta and D. Sharma, *ACS Appl. Nano Mater.*, 2020, **3**, 2026–2037.
- 30 A. Chowdhury, S. Kunjiappan, T. Panneerselvam, B. Somasundaram and C. Bhattacharjee, *Int. Nano Lett.*, 2017, **7**, 91–122.
- 31 S. M. Hussain, A. K. Javorina, A. M. Schrand, H. M. Duhart, S. F. Ali and J. J. Schlager, *Toxicol. Sci.*, 2006, **92**, 456–463.
- 32 F. Qu, H. Pei, R. Kong, S. Zhu and L. Xia, *Talanta*, 2017, **165**, 136–142.
- 33 S. Khan, A. A. Ansari, A. A. Khan, M. Abdulla, O. Al-Obeed and R. Ahmad, *MedChemComm*, 2016, **7**, 1647–1653.
- 34 D. Jiang, D. Ni, Z. T. Rosenkrans, P. Huang, X. Yan and W. Cai, *Chem. Soc. Rev.*, 2019, **48**, 3683–3704.
- 35 J. Jankowski, K. Ognik, A. Stepniowska, Z. Zduńczyk and K. Kozłowski, *PLoS One*, 2018, **13**, e0201487.
- 36 N. Polley, S. Saha, A. Adhikari, S. Banerjee, S. Darbar, S. Das and S. K. Pal, *Nanomedicine*, 2015, **10**, 2349–2363.
- 37 Y. Hao, L. Wang, B. Zhang, D. Li, D. Meng, J. Shi, H. Zhang, Z. Zhang and Y. Zhang, *Int. J. Nanomed.*, 2016, **11**, 1759.
- 38 S. D. Anderson, V. V. Gwenin and C. D. Gwenin, *Nanoscale Res. Lett.*, 2019, **14**, 1–16.
- 39 B. Ding, S. Shao, C. Yu, B. Teng, M. Wang, Z. Cheng, K. L. Wong, P. A. Ma and J. Lin, *Adv. Mater.*, 2018, **30**, 1802479.
- 40 L. Alessio, M. Campagna and R. Lucchini, *Am. J. Ind. Med.*, 2007, **50**, 779–787.
- 41 Journal. *Asian metal*, *Metalpedia*. Weblink: <http://metalpedia.asianmetal.com/metal/manganese/history.shtml>.
- 42 A. Sharma and R. M. Singh, *Heritage*, 2021, **4**, 1970–1994.
- 43 Journal. *RSC*, Weblink: <https://www.rsc.org/periodic-table/element/25/manganese>.
- 44 A. R. Reddi, L. T. Jensen and V. C. Culotta, *Chem. Rev.*, 2009, **109**, 4722–4732.
- 45 P. D. Blanc, *NeuroToxicology*, 2018, **64**, 5–11.
- 46 M. M. Thackeray, J. R. Croy, E. Lee, A. Gutierrez, M. He, J. S. Park, B. T. Yonemoto, B. R. Long, J. D. Blauwkamp, C. S. Johnson, Y. Shin and W. I. F. David, *Sustainable Energy Fuels*, 2018, **2**, 1375–1397.
- 47 O. Sparenberg, *Extr. Ind. Soc.*, 2019, **6**, 842–854.
- 48 K. J. Horning, S. W. Caito, K. G. Tipps, A. B. Bowman and M. Aschner, *Annu. Rev. Nutr.*, 2015, **35**, 71–108.
- 49 J. Roth, S. Ponzoni and M. Aschner, *Met. Ions Life Sci.*, 2013, **12**, 169–201.
- 50 T. E. Kehl-Fie and E. P. Skaar, *Curr. Opin. Chem. Biol.*, 2010, **14**, 218–224.
- 51 H. Haase, *Immunity*, 2018, **48**, 616–618.
- 52 R. H. Hartman, G. Matrone and G. H. Wise, *J. Nutr.*, 1955, **57**, 429–439.
- 53 E. B. Kurutas, *Nutr. J.*, 2016, **15**, 71–71.
- 54 A. Blanco and G. Blanco, in *Med. Biochem.*, ed. A. Blanco and G. Blanco, Academic Press, 2017, pp. 153–175, DOI: 10.1016/B978-0-12-803550-4.00008-2.
- 55 R. B. Rucker, A. J. Fascetti and C. L. Keen, in *Clin. Biochem. Domestic Animals*, ed. J. J. Kaneko, J. W. Harvey and M. L. Bruss, Academic Press, San Diego, 6th edn, 2008, pp. 663–693, DOI: 10.1016/B978-0-12-370491-7.00022-2.
- 56 P. Chen, J. Bornhorst and M. Aschner, *Front. Biosci.-Landmark*, 2018, **23**, 1655–1679.
- 57 C. Molina-Poveda, in *Aquafeed Formulation*, ed. S. F. Nates, Academic Press, San Diego, 2016, pp. 75–216, DOI: 10.1016/B978-0-12-800873-7.00004-X.
- 58 C. L. Keen and S. Zidenberg-Cherr, in *Encyclopedia of Food Sciences and Nutrition*, ed. B. Caballero, Academic Press, Oxford, 2nd edn, 2003, pp. 3686–3691, DOI: 10.1016/B0-12-227055-X/00732-X.
- 59 I. I. Ahmetov and O. N. Fedotovskaya, in *Adv. Clin. Chem.*, ed. G. S. Makowski, Elsevier, 2015, vol. 70, pp. 247–314.
- 60 I. Rahman and S. K. Biswas, in *Encyclopedia of Respiratory Medicine*, ed. G. J. Laurent and S. D. Shapiro, Academic Press, Oxford, 2006, pp. 258–266, DOI: 10.1016/B0-12-370879-6/00283-0.
- 61 N. Singh, M. Geethika, S. M. Eswarappa and G. Mugesh, *Chem. – Eur. J.*, 2018, **24**, 8393–8403.
- 62 L.-Y. Chau and H.-H. Tai, *Biochim. Biophys. Acta, Lipids Lipid Metab.*, 1988, **963**, 436–444.
- 63 A. R. Kornblihtt, M. M. Flawia and H. N. Torres, *Biochemistry*, 1981, **20**, 1262–1267.
- 64 J. Sekiguchi and S. Shuman, *Biochemistry*, 1997, **36**, 9073–9079.
- 65 A. Balakrishnan, M. Padigaru and A. Morde, in *Nutraceuticals in Brain Health and Beyond*, ed. D. Ghosh, Academic Press, 2021, pp. 281–292, DOI: 10.1016/B978-0-12-820593-8.00019-7.
- 66 D. Leu, I. Spasojevic, H. Nguyen, B. Deng, A. Tovmasyan, T. Weitner, R. S. Sampaio, I. Batinic-Haberle and T.-T. Huang, *Redox Biol.*, 2017, **12**, 864–871.
- 67 J. G. Anderson, S. C. Fordahl, P. T. Cooney, T. L. Weaver, C. L. Colyer and K. M. Erikson, *Brain Res.*, 2009, **1281**, 1–14.
- 68 D. L. Vesely, *Mol. Cell. Biochem.*, 1985, **66**, 145–149.
- 69 J. K. Bashkin and L. A. Jenkins, *Comments Inorg. Chem.*, 1994, **16**, 77–93.
- 70 D. S. Harischandra, S. Ghaisas, G. Zenitsky, H. Jin, A. Kanthasamy, V. Anantharam and A. G. Kanthasamy, *Front. Neurosci.*, 2019, **13**, 654.
- 71 A. M. Polyanichko, V. V. Andrushchenko, E. V. Chikhirzhina, V. I. Vorob'ev and H. Wieser, *Nucleic Acids Res.*, 2004, **32**, 989–996.
- 72 E. H. Chu and W. M. Generoso, *Mutation, cancer, and malformation*, Springer Science & Business Media, 2012.

- 73 M. Gross and D. A. Kaplansky, *Biochim. Biophys. Acta*, 1983, **740**, 255–263.
- 74 D. L. Baly, C. L. Keen and L. S. Hurley, *Biol. Trace Elem. Res.*, 1986, **11**, 201–212.
- 75 G. S. Shukla and S. V. Chandra, *Acta Pharmacol. Toxicol.*, 1982, **51**, 209–216.
- 76 M. R. Bryan and A. B. Bowman, *Adv. Neurobiol.*, 2017, **18**, 113–142.
- 77 E. de Lamirande and G. L. Plaa, *Arch. Int. Pharmacodyn. Ther.*, 1979, **239**, 24–35.
- 78 T. P. Moyer, in *Pharmacol. Ther.*, ed. S. A. Waldman, A. Terzic, L. J. Egan, J.-L. Elghozi, A. Jahangir, G. C. Kane, W. K. Kraft, L. D. Lewis, J. D. Morrow, L. V. Zingman, D. R. Abernethy, A. J. Atkinson, N. L. Benowitz, D. C. Brater, J. Gray, P. K. Honig, G. L. Kearns, B. A. Levey, S. P. Spielberg, R. Weinshilboum and R. L. Woosley, W. B. Saunders, Philadelphia, 2009, pp. 1213–1220, DOI: 10.1016/B978-1-4160-3291-5.50090-1.
- 79 J. Kawano, D. M. Ney, C. L. Keen and B. O. Schneeman, *J. Nutr.*, 1987, **117**, 902–906.
- 80 K. J. Thompson, J. Hein, A. Baez, J. C. Sosa and M. Wessling-Resnick, *Am. J. Physiol.: Gastrointest. Liver Physiol.*, 2018, **315**, G351–G363.
- 81 L. Tillman, *Biosci. Horiz.: Int. Dent. J. Stud. Res.*, 2019, **11**, DOI: 10.1093/biohorizons/hzy012.
- 82 J. Yao, Y. Cheng, M. Zhou, S. Zhao, S. Lin, X. Wang, J. Wu, S. Li and H. Wei, *Chem. Sci.*, 2018, **9**, 2927–2933.
- 83 Q. Ye, J. E. Park, K. Gugnani, S. Betharia, A. Pino-Figueroa and J. Kim, *Metalomics: Integr. Biometal Sci.*, 2017, **9**, 1028–1046.
- 84 J. S. Crossgrove and R. A. Yokel, *Neurotoxicology*, 2004, **25**, 451–460.
- 85 L. S. Hurley, C. L. Keen and D. L. Baly, *Neurotoxicology*, 1984, **5**, 97–104.
- 86 P. L. Goering and C. D. Klaassen, *Biochem. Pharmacol.*, 1985, **34**, 1371–1379.
- 87 E. S. Koh, S. J. Kim, H. E. Yoon, J. H. Chung, S. Chung, C. W. Park, Y. S. Chang and S. J. Shin, *BMC Endocr. Disord.*, 2014, **14**, 24–24.
- 88 A. H. Rubenstein, N. W. Levin and G. A. Elliott, *Lancet*, 1962, **2**, 1348–1351.
- 89 D. L. Baly, D. L. Curry, C. L. Keen and L. S. Hurley, *J. Nutr.*, 1984, **114**, 1438–1446.
- 90 J. H. Gong, K. Lo, Q. Liu, J. Li, S. Lai, A. H. Shadyab, C. Arcan, L. Snetelaar and S. Liu, *Diabetes Care*, 2020, **43**, 1344.
- 91 D. L. Baly, J. S. Schneiderman and A. L. Garcia-Welsh, *J. Nutr.*, 1990, **120**, 1075–1079.
- 92 E. Bulet and S. K. Jain, *J. Biol. Chem.*, 2013, **288**, 6409–6416.
- 93 N. Wang, X. Cao, G. Lin and Y. Shihe, *Nanotechnology*, 2007, **18**, 475605.
- 94 Y. Chen, Y. Hong, Y. Ma and J. Li, *J. Alloys Compd.*, 2010, **490**, 331–335.
- 95 M. Jayandran, M. M. Haneefa and V. Balasubramanian, *J. Appl. Pharm. Sci.*, 2015, **5**, 105–110.
- 96 V. Kumar, K. Singh, S. Panwar and S. K. Mehta, *Int. Nano Lett.*, 2017, **7**, 123–131.
- 97 A. Sinha, V. N. Singh, B. R. Mehta and S. K. Khare, *J. Hazard. Mater.*, 2011, **192**, 620–627.
- 98 A. Sukhdev, M. Challa, L. Narayani, A. S. Manjunatha, P. R. Deepthi, J. V. Angadi, P. Mohan Kumar and M. Pasha, *Heliyon*, 2020, **6**, e03245.
- 99 X. Liu, C. Chen, Y. Zhao and B. Jia, *J. Nanomater.*, 2013, **2013**, 736375.
- 100 T. Soejima, K. Nishizawa and R. Isoda, *J. Colloid Interface Sci.*, 2018, **510**, 272–279.
- 101 D. Ghosh, S. Bhandari and D. Khastgir, *Phys. Chem. Chem. Phys.*, 2016, **18**, 32876–32890.
- 102 M. B. Ward, R. Brydson and R. F. Cochrane, *J. Phys.: Conf. Ser.*, 2006, **26**, 296–299.
- 103 C. Martinez de la Torre, J. H. Grossman, A. A. Bobko and M. F. Bennewitz, *PLoS One*, 2020, **15**, e0239034.
- 104 B. Ding, P. Zheng, P. A. Ma and J. Lin, *Adv. Mater.*, 2020, **32**, 1905823.
- 105 T. Simao, D. M. Chevrier, J. Jakobi, A. Korinek, G. Goupil, M. Lau, S. Garbarino, P. Zhang, S. Barcikowski, M.-A. Fortin and D. Guay, *J. Phys. Chem. C*, 2016, **120**, 22635–22645.
- 106 J.-G. Lee, P. Li, C.-J. Choi and X.-L. Dong, *Thin Solid Films*, 2010, **519**, 81–85.
- 107 V. Hoseinpour and N. Ghaemi, *J. Photochem. Photobiol., B*, 2018, **189**, 234–243.
- 108 S. Waghmare, A. Deshmukh, S. Kulkarni and L. Oswaldo, *Univers. J. Environ. Res. Technol.*, 2011, **1**, 64–69.
- 109 J. Singh, T. Dutta, K.-H. Kim, M. Rawat, P. Samddar and P. Kumar, *J. Nanobiotechnol.*, 2018, **16**, 84.
- 110 D. Zhang, X.-L. Ma, Y. Gu, H. Huang and G.-W. Zhang, *Front. Chem.*, 2020, **8**, 799.
- 111 S. Irvani, *Green Chem.*, 2011, **13**, 2638–2650.
- 112 S. Jana, S. Pande, A. K. Sinha, S. Sarkar, M. Pradhan, M. Basu, S. Saha and T. Pal, *J. Phys. Chem. C*, 2009, **113**, 1386–1392.
- 113 J. R. Carney, B. R. Dillon and S. P. Thomas, *Eur. J. Org. Chem.*, 2016, 3912–3929.
- 114 S. Zhu, S.-H. Ho, C. Jin, X. Duan and S. Wang, *Environ. Sci. Nano*, 2020, **7**, 368–396.
- 115 R. Dardouri, A. Gannouni and M. S. Zina, *Adv. Mater. Sci. Eng.*, 2019, **2019**, 6024876.
- 116 S. Dey and V. V. Praveen Kumar, *Curr. Opin. Green Sustainable Chem.*, 2020, **3**, 100012.
- 117 A. J. Wu, J. E. Penner-Hahn and V. L. Pecoraro, *Chem. Rev.*, 2004, **104**, 903–938.
- 118 X. Liu, Q. Wang, H. Zhao, L. Zhang, Y. Su and Y. Lv, *Analyst*, 2012, **137**, 4552–4558.
- 119 N. Singh, M. A. Savanur, S. Srivastava, P. D'Silva and G. Mughesh, *Nanoscale*, 2019, **11**, 3855–3863.
- 120 J. Liu, L. Meng, Z. Fei, P. J. Dyson, X. Jing and X. Liu, *Biosens. Bioelectron.*, 2017, **90**, 69–74.
- 121 F. Chen, M. Bai, Y. Zhao, K. Cao, X. Cao and Y. Zhao, *Anal. Chem.*, 2018, **90**, 2271–2276.
- 122 P. Zhao, Y. Zhu, X. Yang, J. Shen, X. Jiang, J. Zong and C. Li, *Dalton Trans.*, 2014, **43**, 451–457.
- 123 A. Greene, J. Hashemi and Y. Kang, *Nanotechnology*, 2020, **32**, 025713.

- 124 J. K. Patra, G. Das, L. F. Fraceto, E. V. R. Campos, M. D. P. Rodriguez-Torres, L. S. Acosta-Torres, L. A. Diaz-Torres, R. Grillo, M. K. Swamy, S. Sharma, S. Habtemariam and H.-S. Shin, *J. Nanobiotechnol.*, 2018, **16**, 71–71.
- 125 L. Yan, J. Shen, J. Wang, X. Yang, S. Dong and S. Lu, *Dose-Response*, 2020, **18**, 1559325820936161–1559325820936161.
- 126 S. Senapati, A. K. Mahanta, S. Kumar and P. Maiti, *Signal Transduction Targeted Ther.*, 2018, **3**, 7.
- 127 M. J. Mitchell, M. M. Billingsley, R. M. Haley, M. E. Wechsler, N. A. Peppas and R. Langer, *Nat. Rev. Drug Discovery*, 2021, **20**, 101–124.
- 128 M. U. Farooq, V. Novosad, E. A. Rozhkova, H. Wali, A. Ali, A. A. Fateh, P. B. Neogi, A. Neogi and Z. Wang, *Sci. Rep.*, 2018, **8**, 2907.
- 129 I. Ghiuță and D. Cristea, *Adv. Drug Delivery Rev.*, 2020, 347–371, DOI: 10.1016/B978-0-08-102985-5.00015-2.
- 130 X. Zeng, J. Sun, S. Li, J. Shi, H. Gao, W. Sun Leong, Y. Wu, M. Li, C. Liu, P. Li, J. Kong, Y.-Z. Wu, G. Nie, Y. Fu and G. Zhang, *Nat. Commun.*, 2020, **11**, 567.
- 131 H. Fan, Z. Zhao, G. Yan, X. Zhang, C. Yang, H. Meng, Z. Chen, H. Liu and W. Tan, *Angew. Chem., Int. Ed.*, 2015, **54**, 4801–4805.
- 132 J. Xu, W. Han, P. Yang, T. Jia, S. Dong, H. Bi, A. Gulzar, D. Yang, S. Gai, F. He, J. Lin and C. Li, *Adv. Funct. Mater.*, 2018, **28**, 1803804.
- 133 Q. Ren, K. Yang, R. Zou, Z. Wan, Z. Shen, G. Wu, Z. Zhou, Q. Ni, W. Fan, J. Hu and Y. Liu, *Nanoscale*, 2019, **11**, 23021–23026.
- 134 G. Wang, D. Zhao, Y. Ma, Z. Zhang, H. Che, J. Mu, X. Zhang and Z. Zhang, *Appl. Surf. Sci.*, 2018, **428**, 258–263.
- 135 Z. Zhang and Y. Ji, *Ind. Eng. Chem. Res.*, 2019, **58**, 2991–2999.
- 136 T. Tonini, F. Rossi and P. P. Claudio, *Oncogene*, 2003, **22**, 6549–6556.
- 137 A. K. Barui, S. K. Nethi, S. Haque, P. Basuthakur and C. R. Patra, *ACS Appl. Bio Mater.*, 2019, **2**, 5492–5511.
- 138 G. Niu and X. Chen, *Curr. Drug Targets*, 2010, **11**, 1000–1017.
- 139 R. I. Teleanu, C. Chircov, A. M. Grumezescu and D. M. Teleanu, *J. Clin. Med.*, 2020, **9**, 84.
- 140 M. Majidifard and M. Hassanpour-Ezatti, *Daneshvar Med.*, 2016, **23**, 21–28.
- 141 C.-C. Chang, T. K. Dinh, Y.-A. Lee, F.-N. Wang, Y.-C. Sung, P.-L. Yu, S.-C. Chiu, Y.-C. Shih, C.-Y. Wu and Y.-D. Huang, *ACS Appl. Bio Mater.*, 2020, **12**, 44407–44419.
- 142 U. Kamran, H. N. Bhatti, M. Iqbal, S. Jamil and M. Zahid, *J. Mol. Struct.*, 2019, **1179**, 532–539.
- 143 E. Azhir, R. Etefagh, N. Shahtahmasebi, M. Mashreghi and P. Pordeli, *Phys. Chem. Res.*, 2015, **3**, 197–204.
- 144 Y. Lin, H. Betts, S. Keller, K. Cariou and G. Gasser, *Chem. Soc. Rev.*, 2021, **50**, 10346–10402.
- 145 B. Krishnan and S. Mahalingam, *Res. Chem. Intermed.*, 2017, **43**, 2351–2365.
- 146 L. Singh, H. G. Kruger, G. E. M. Maguire, T. Govender and R. Parboosing, *Ther. Adv. Infect. Dis.*, 2017, **4**, 105–131.
- 147 K. Maduray and R. Parboosing, *Biol. Trace Elem. Res.*, 2021, **199**, 3159–3176.
- 148 M. V. Nesterenko, K. M. Woods and S. J. Upton, *Biol. Trace Elem. Res.*, 1997, **56**, 243–253.
- 149 J.-P. Vartanian, M. Sala, M. Henry, S. Wain-Hobson and A. Meyerhans, *J. Gen. Virol.*, 1999, **80**, 1983–1986.
- 150 N. T. Mahlangeni, J. Magura, R. Moodley, H. Baijnath and H. Chenia, *Chem. Pap.*, 2020, **74**, 4253–4265.
- 151 S. Pardhiya, E. Priyadarshini and P. Rajamani, *SN Appl. Sci.*, 2020, **2**, 1–12.
- 152 Y. Wang, Y. Song, G. Zhu, D. Zhang and X. Liu, *Chin. Chem. Lett.*, 2018, **29**, 1685–1688.
- 153 W. Zhu, Z. Dong, T. Fu, J. Liu, Q. Chen, Y. Li, R. Zhu, L. Xu and Z. Liu, *Adv. Funct. Mater.*, 2016, **26**, 5490–5498.
- 154 Z. Yu, Q. Li, J. Wang, Y. Yu, Y. Wang, Q. Zhou and P. Li, *Nanoscale Res. Lett.*, 2020, **15**, 1–14.
- 155 Z. Ma, X. Jia, J. Bai, Y. Ruan, C. Wang, J. Li, M. Zhang and X. Jiang, *Adv. Funct. Mater.*, 2017, **27**, 1604258.
- 156 J. Peng, Q. Yang, W. Li, L. Tan, Y. Xiao, L. Chen, Y. Hao and Z. Qian, *ACS Appl. Mater. Interfaces*, 2017, **9**, 44410–44422.
- 157 J. Liu, G. Wu, Z. Tang, Q. Sun, J. Wu and R. Lv, *Front. Mater.*, 2019, **6**, 286.
- 158 Y. Cheng, S. Zhang, N. Kang, J. Huang, X. Lv, K. Wen, S. Ye, Z. Chen, X. Zhou and L. Ren, *ACS Appl. Mater. Interfaces*, 2017, **9**, 19296–19306.
- 159 C. Sun, Y. Liu, R. Zhou, L. Yao, R. Wang, W. Zang and W. Meng, *ACS Appl. Bio Mater.*, 2019, **2**, 4747–4755.
- 160 M. Wu, P. Hou, L. Dong, L. Cai, Z. Chen, M. Zhao and J. Li, *Int. J. Nanomed.*, 2019, **14**, 4781–4800.
- 161 C. Ji, Z. Lu, Y. Xu, B. Shen, S. Yu and D. Shi, *J. Biomed. Mater. Res., Part B*, 2018, **106**, 2544–2552.
- 162 J. Li, D. Li, R. Yuan and Y. Xiang, *ACS Appl. Mater. Interfaces*, 2017, **9**, 5717–5724.
- 163 J. H. Han, L. Sudheendra and M. I. Kennedy, *Anal. Bioanal. Chem.*, 2015, **407**, 5243–5247.
- 164 J. Yuan, Y. Cen, X.-J. Kong, S. Wu, C.-L. Liu, R.-Q. Yu and X. Chu, *ACS Appl. Mater. Interfaces*, 2015, **7**, 10548–10555.
- 165 Z. Zhen and J. Xie, *Theranostics*, 2012, **2**, 45.
- 166 C. M. de la Torre and M. F. Bennewitz, *J. Visualized Exp.*, 2020, e61572.
- 167 B. Song, W. Shi, W. Shi, X. Qin, H. Ma, M. Tan, W. Zhang, L. Guo and J. Yuan, *Nanoscale*, 2019, **11**, 6784–6793.
- 168 J. Li, C. Wu, P. Hou, M. Zhang and K. Xu, *Biosens. Bioelectron.*, 2018, **102**, 1–8.
- 169 J. Zhu, H. Li, Z. Xiong, M. Shen, P. S. Conti, X. Shi and K. Chen, *ACS Appl. Mater. Interfaces*, 2018, **10**, 34954–34964.
- 170 Y. Zhan, S. Shi, E. B. Ehlerding, S. A. Graves, S. Goel, J. W. Engle, J. Liang, J. Tian and W. Cai, *ACS Appl. Mater. Interfaces*, 2017, **9**, 38304–38312.
- 171 A. Asaikkutti, P. S. Bhavan, K. Vimala, M. Karthik and P. Cheruparambath, *J. Trace Elem. Med. Biol.*, 2016, **35**, 7–17.

- 172 S. Chen, J. Zhu, X. Wu, Q. Han and X. Wang, *ACS Nano*, 2010, **4**, 2822–2830.
- 173 H.-Y. Wang, F.-X. Xiao, L. Yu, B. Liu and X. W. Lou, *Small*, 2014, **10**, 3181–3186.
- 174 B. Xu, C. R. Fell, M. Chi and Y. S. Meng, *Energy Environ. Sci.*, 2011, **4**, 2223–2233.
- 175 S. A. Moon, B. K. Salunke, B. Alkotaini, E. Sathiyamoorthi and B. S. Kim, *IET Nanobiotechnol.*, 2015, **9**, 220–225.
- 176 I. Djerdj, D. Arçon, Z. Jagličić and M. Niederberger, *J. Phys. Chem. C*, 2007, **111**, 3614–3623.
- 177 S. Biswas, S. Kar and S. Chaudhuri, *J. Phys. Chem. B*, 2005, **109**, 17526–17530.
- 178 S. Bajpai and M. Chaudhuri, *Int. J. Environ. Eng.*, 1999, **125**, 782–784.
- 179 L. M. Camacho, R. R. Parra and S. Deng, *J. Hazard. Mater.*, 2011, **189**, 286–293.
- 180 M. M. Najafpour, F. Rahimi, M. Amini, S. Nayeri and M. Bagherzadeh, *Dalton Trans.*, 2012, **41**, 11026–11031.
- 181 Y. Ye, I. A. Medina-Velo, K. Cota-Ruiz, F. Moreno-Olivas and J. L. Gardea-Torresdey, *Ecotoxicol. Environ. Saf.*, 2019, **184**, 109671.
- 182 E. Gillispie, S. Taylor, N. Qafoku and M. Hochella, *Environ. Chem.*, 2019, **16**, 377–390.
- 183 Y. Ye, K. Cota-Ruiz, J. A. Hernández-Viezcás, C. Valdés, I. A. Medina-Velo, R. S. Turley, J. R. Peralta-Videa and J. L. Gardea-Torresdey, *ACS Sustainable Chem. Eng.*, 2020, **8**, 1427–1436.
- 184 S. Pradhan, P. Patra, S. Das, S. Chandra, S. Mitra, K. K. Dey, S. Akbar, P. Palit and A. Goswami, *Environ. Sci. Technol.*, 2013, **47**, 13122–13131.
- 185 S. Pradhan, P. Patra, S. Mitra, K. K. Dey, S. Jain, S. Sarkar, S. Roy, P. Palit and A. Goswami, *J. Agric. Food Chem.*, 2014, **62**, 8777–8785.
- 186 S. Mukherjee and C. R. Patra, *Nanoscale*, 2016, **8**, 12444–12470.
- 187 D. Milatovic and R. C. Gupta, in *Veterinary Toxicology*, ed. R. C. Gupta, Academic Press, 3rd edn, 2018, pp. 445–454, DOI: 10.1016/B978-0-12-811141-0.00030-1.
- 188 M. Ou, J. Huang, X. Yang, X. He, K. Quan, Y. Yang, N. Xie, J. Li and K. Wang, *ChemBioChem*, 2018, **19**, 147–152.
- 189 I. Razumov, E. Zav'yalov, S. Y. Troitskii, A. Romashchenko, D. Petrovskii, K. Kuper and M. Moshkin, *Bull. Exp. Biol. Med.*, 2017, **163**, 561–565.
- 190 T. Li, T. Shi, X. Li, S. Zeng, L. Yin and Y. Pu, *Int. J. Environ. Res. Public Health*, 2014, **11**, 7918–7930.
- 191 D. He, X. Yang, X. He, K. Wang, X. Yang, X. He and Z. Zou, *Chem. Commun.*, 2015, **51**, 14764–14767.
- 192 X. Yan, Y. Song, C. Zhu, J. Song, D. Du, X. Su and Y. Lin, *ACS Appl. Mater. Interfaces*, 2016, **8**, 21990–21996.
- 193 B. Zhou, J. Zhao, Y. Qiao, Q. Wei, J. He, W. Li, D. Zhong, F. Ma, Y. Li and M. Zhou, *Appl. Mater. Today*, 2018, **13**, 285–297.
- 194 W. Xu, J. Sun, L. Li, X. Peng, R. Zhang and B. Wang, *Biomater. Sci.*, 2018, **6**, 207–215.
- 195 N. Yousefalizadegan, Z. Mousavi, T. Rastegar, Y. Razavi and P. Najafizadeh, *Int. J. Reprod. Biomed.*, 2019, **17**, 361.
- 196 L. Feng, R. Xie, C. Wang, S. Gai, F. He, D. Yang, P. Yang and J. Lin, *ACS Nano*, 2018, **12**, 11000–11012.
- 197 P. Zhu, Y. Chen and J. Shi, *ACS Nano*, 2018, **12**, 3780–3795.
- 198 A. C. Martins Jr., P. Morcillo, O. M. Ijomone, V. Venkataramani, F. E. Harrison, E. Lee, A. B. Bowman and M. Aschner, *Int. J. Environ. Res. Public Health*, 2019, **16**, 3546.
- 199 Y. Tong, H. Yang, X. Tian, H. Wang, T. Zhou, S. Zhang, J. Yu, T. Zhang, D. Fan, X. Guo, T. Tabira, F. Kong, Z. Chen, W. Xiao and D. Chui, *J. Alzheimer's Dis.*, 2014, **42**, 865–878.
- 200 H. Dieter, T. Bayer and G. Multhaup, *Acta Hydrochim. Hydrobiol.*, 2005, **33**, 72–78.
- 201 V. A. Fitsanakis, C. Au, K. M. Erikson and M. Aschner, *Neurochem. Int.*, 2006, **48**, 426–433.
- 202 N. Ammal Kaidery and B. Thomas, *Neurochem. Int.*, 2018, **117**, 91–113.
- 203 D. Milatovic, Z. Yin, R. C. Gupta, M. Sidoryk, J. Albrecht, J. L. Aschner and M. Aschner, *Toxicol. Sci.*, 2007, **98**, 198–205.
- 204 T. V. Peres, M. R. Schettinger, P. Chen, F. Carvalho, D. S. Avila, A. B. Bowman and M. Aschner, *BMC Pharmacol. Toxicol.*, 2016, **17**, 57.
- 205 R. G. Lucchini, C. J. Martin and B. C. Doney, *NeuroMol. Med.*, 2009, **11**, 311–321.
- 206 R. G. Lucchini, S. Guazzetti, S. Zoni, F. Donna, S. Peter, A. Zacco, M. Salmistraro, E. Bontempi, N. J. Zimmerman and D. R. Smith, *Neurotoxicology*, 2012, **33**, 687–696.
- 207 I. Ghosh, A. Sadhu, Y. Moriyasu, M. Bandyopadhyay and A. Mukherjee, *Mutat. Res., Genet. Toxicol. Environ. Mutagen.*, 2019, **842**, 146–157.
- 208 A. Kaushik, *Front. Nanotechnol.*, 2019, **1**, 1.
- 209 Y. Yang, Z. Qin, W. Zeng, T. Yang, Y. Cao, C. Mei and Y. Kuang, *Nanotechnol. Rev.*, 2017, **6**, 279–289.
- 210 N. Desai, *AAPS J.*, 2012, **14**, 282–295.
- 211 D. Rosenblum, N. Joshi, W. Tao, J. M. Karp and D. Peer, *Nat. Commun.*, 2018, **9**, 1410.
- 212 S. P. Singh, M. Kumari, S. I. Kumari, M. F. Rahman, M. Mahboob and P. Grover, *J. Appl. Toxicol.*, 2013, **33**, 1165–1179.
- 213 S. Barua and S. Mitragotri, *Nano Today*, 2014, **9**, 223–243.
- 214 H. Bahadar, F. Maqbool, K. Niaz and M. Abdollahi, *Iran. Biomed. J.*, 2016, **20**, 1–11.
- 215 S. L. O'Neal and W. Zheng, *Curr. Environ. Health Rep.*, 2015, **2**, 315–328.
- 216 C. O. Dimkpa, U. Singh, I. O. Adisa, P. S. Bindraban, W. H. Elmer, J. L. Gardea-Torresdey and J. C. White, *Agronomy*, 2018, **8**, 158.
- 217 S. Alarifi, D. Ali and S. Alkahtani, *BioMed Res. Int.*, 2017, **2017**, 5478790.
- 218 J. Fredericks, S. Senapati and M. J. Wannemuehler, *F1000Research*, 2020, **9**, 975.
- 219 C. L. Ventola, *P T*, 2017, **42**, 742–755.
- 220 D. Bobo, K. Robinson, J. Islam, K. Thurecht and S. Corrie, *Pharm. Res.*, 2016, **33**, 2373–2387.